Skip to main content
SpringerLink
Log in

Prostatakarzinom

Epidemiologie, Ätiologie, Pathologie, Diagnostik, prognostische Faktoren

  • Chapter
Uroonkologie

Zusammenfassung

Die Inzidenz des Prostatakarzinoms stieg 1995 auf „epidemisches“ Niveau. Dies trifft vor allem auf die USA zu; denn zwischen 1979 und 1995 erhöhte sich die Zahl der Erkrankten von 64000 auf 244000 (Wingo et al. 1995). In Deutschland läßt sich diese Inzidenzsteigerung um den Faktor 4 nicht beobachten, 1991 erkrankten etwa 16000 und 1995 etwa 20000 Männer (Hölzel et al, 1991; Hölzel, 1995) (Abb. 6.1).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Adami HO, Norlén BJ, Malker B, Meirik O (1986) Long-term survival in prostatic carcinoma, with special reference to age as a prognostic factor. Scand J Urol Nephrol 20:107–112

    Article  CAS  PubMed  Google Scholar 

  • Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckly AR, Sullivan LD (1993) Effects of intermittent androgen suppression on androgen-dependent tumor. Apoptosis and serum PSA. Cancer 71:2782–2790

    Article  CAS  PubMed  Google Scholar 

  • Altwein JE (1994) Is hormone therapy indicated in localised carcinoma of the prostate? In: Murphy G, Khoury S, Chatelain C, Denis L (eds) 4th International Symposium on Recent Advances in Urological Cancer. S.C.I. Jersey, pp 293

    Google Scholar 

  • Altwein JE, Faul P, Rübben H (1994) Beeinflußt eine abwartende Therapie Progression und überleben beim Prostatakarzinom? Urologe B 34:159–164

    Google Scholar 

  • Andriole GL, Kavoussi LR, Torrence RJ et al. (1988) Transrectal ultrasonography in the diagnosis and staging of carcinoma of the prostate. J Urol 140:758–760

    CAS  PubMed  Google Scholar 

  • Antoni E de, Crawford ED (1995) Neuere Multicenterstudienprotokolle in den USA für Patienten mit einem metastasierenden Prostatakarzinom. Urologe A 34:382–388

    Google Scholar 

  • Auberger T, Zilch HG, Lukas P et al. (1989) Stellenwert der MR-Tomographie in der bildgebenden urologischen Diagnostik. In: Nagel R (Hrsg): Aktuelle Standortbestimmung der konservativen Therapie des Prostatakarzinoms. De Gruyter, Berlin, pp 35–55

    Google Scholar 

  • Babaian RJ, Mettlin C, Krane R et al. (1992) The Relationship of prostate-specific antigen to digital rectal examination and transrectal ultrasonography. Cancer 69 (5): 1195–1200

    Article  CAS  PubMed  Google Scholar 

  • Bastacky SS, Walsh PC, Epstein JI (1991) Needle biopsy associated tumor tracking of adenocarcinoma of the prostate. J Urol 145:1003–1007

    CAS  PubMed  Google Scholar 

  • Bennett CL, Greenfield S, Aronow H, Ganz P, Vogelzang NJ, Elashoff RM (1991) Patterns of care related to age of man with prostate cancer. Cancer 67: 2633–2641

    Article  CAS  PubMed  Google Scholar 

  • Berner A, Waere H, Nesland JM, Paus E, Danielsen HE, Fossa SD (1995) DNA ploidy, serum prostate specific antigen, histological grade and immunohistochemistry as predictive parameters of lymph node metastases in T 1-T 3/M 0 prostatic adenocarcinoma. Br J Urol 75:26–32

    Article  CAS  PubMed  Google Scholar 

  • Berry WR, Laszlo J, Cox E, Walker N, Paulson DF (1979) Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate. Cancer 44:763–775

    Article  CAS  PubMed  Google Scholar 

  • Bertagna C, Géry A de, Hucher M, Zanirato F and J (1994) Efficacy of the combination of nilutamide plus orchidectomy in seven radomized double-blind trials (1056 patients). Brit J Urol 73:396–402

    Article  CAS  PubMed  Google Scholar 

  • Boccon-Gibod L (1993) Nonsteroidal antiandrogen monotherapy of metastatic cancer of the prostate. Eur Urol 24 [Suppl 2]: 77–80

    PubMed  Google Scholar 

  • Bonkhoff H, Stein U, Welter C, Remberger K (1995) Differential expression of the pS2 protein in the human prostate and prostate cancer: Association with premalignant changes and neuroendocrine differentiation. Human Pathol 26:824–828

    Article  CAS  Google Scholar 

  • Bostwick DG (1995) High grade prostatic intraepithelial neoplasia the most likely precursor of prostate cancer. Cancer 75 [Suppl 7]: 1823–1826

    Article  Google Scholar 

  • Bostwick DG, Graham SD, Napalkov P et al. (1993) Staging of early prostate cancer: a proposed tumor volume-based prognostic index. Urology 41:403–411

    Article  CAS  PubMed  Google Scholar 

  • Brawer MK (1995) How to use PSA in the early detection or screening for prostatic carcinoma. CA Cancer J Clin 45:148–164

    Article  CAS  PubMed  Google Scholar 

  • Brawer MK, Beattie J, Wener MH (1993) Screening for prostatic carcinoma with PSA: Results of the second year. J Urol 150:106–109

    CAS  PubMed  Google Scholar 

  • Bressel M (1989) Radikale retropubische Prostatektomie (RRP). In: Sommerkamp H, Altwein JE (Hrsg) Prostatakarzinom — Spektrum der kurativen Therapie. Karger, Basel, S 146–173

    Google Scholar 

  • Bretan PN, Williams RD (1987) Imaging techniques in the diagnosis and pelvic staging of prostatic cancer. In: Bruce AW, Trachtenberg J (eds) Adenocarcinoma of the prostate. Springer, Berlin Heidelberg New York, pp 83–106

    Chapter  Google Scholar 

  • Bretton PR, Melamed MR, Fair WR, Cote RJ (1994) Detection of occult micrometastases in the bone marrow of patients with prostate carcinoma. Prostate 25:108–114

    Article  CAS  PubMed  Google Scholar 

  • Brewster SF, Gillatt DA (1993) Advanced prostate cancer: what’s new in hormonal manipulation? Br J Hosp Med 49:710–715

    CAS  PubMed  Google Scholar 

  • Biilow H (1980) Zur Behandlung des fortgeschrittenen Prostatakarzinoms mit Polyoestradiolphos-phat (Estradurin). Med Welt 34:2–4

    Google Scholar 

  • Burke HB, Henson DE (1993) Criteria prognostic factors and for an enhanced prognostic system. Cancer 72:3131–3135

    Article  CAS  PubMed  Google Scholar 

  • Burgers JK, Hinkle GH, Haseman MK (1995) Monoclonal antibody imaging of recurrent and metastatic prostate cancer. Sem Urol 13:103

    CAS  Google Scholar 

  • Byar DP, Mostofi FK, VA Cooperative Urological Research Group (1972) Carcinoma of the prostate: prognostic evaluation of certain pathological features in 208 radical prostatectomies. Cancer 30:5–13

    Article  CAS  PubMed  Google Scholar 

  • Calais da Silva F, Reis E, Costa T, Denis L (1993) Quality of life in patients with prostatic cancer. Cancer 71:1138–1142

    Article  Google Scholar 

  • Carter BS, Ewing CM, Ward WS et al. (1990) Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci 87:8751–8755

    Article  CAS  PubMed  Google Scholar 

  • Carter HB, Pearson JD (1993) PSA velocity for the diagnosis of early prostate cancer. Urol Clin North Am 20:665–670

    CAS  PubMed  Google Scholar 

  • Catalona WJ, Smith DS, Ratliff TL, Basler JW (1993) Detection of organ confined prostate cancer is increased through PSA-based screening. J Am Med Ass 270:948–954

    Article  CAS  Google Scholar 

  • Catalona WJ, Richie JP, De Kernion JB et al. (1994) Comparison of PSA concentration versus PSA density in the early detection of prostate cancer: ROC curves. J Urol 152:2031–2036

    CAS  PubMed  Google Scholar 

  • Chang A, Yeap B, Blum R, Hahn R et al. (1992) A double blind randomized study of primary treatment for stage D2 prostate cancer; diethylstilbestrol (DES) versus flutamide (F). Proc ASCO 11: 202

    Google Scholar 

  • Cheng WS, Frydenberg M, Bergstralh EJ, Larson-Keller JJ, Zincke H (1993) Radical prostatectomy for pathologic stage C prostate cancer: influence of pathologic variables and adjuvant treatment on disease outcome. Urology 42:283

    Article  CAS  PubMed  Google Scholar 

  • Chi S, deVere White RW, Meyers FJ, Siders DB, Lee F, Gumerlock PH (1993) p53 in prostate cancer: Frequent expressed transition mutation. J Natl Cancer Inst 86:926–933

    Article  Google Scholar 

  • Chodak GW, Vogelzang NJ, Caplan RJ et al. (1991) Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. JAMA 265:618–621

    Article  CAS  PubMed  Google Scholar 

  • Chodak GW, Thisted RA, Gerber GS et al. (1994) Results of conservative management of clinically localized prostate cancer. N Engl J Med 330:242–248

    Article  CAS  PubMed  Google Scholar 

  • Chow CC, Daly BD, Burney TL et al. (1994) Complications after laparoscopic pelvic lymphadenectomy: CT diagnosis. AJR 163:353–356

    Article  CAS  PubMed  Google Scholar 

  • Chybowski FM, Larson Keller JJ, Bergstralh EJ et al. (1991) Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer prostate specific antigen is superior to all other clinical parameters. J Urol 145:313

    CAS  PubMed  Google Scholar 

  • Clark TD (1987) Nuclear roundness factor a quantitative approach to grading in prostate carcinoma, reliability of needle biopsy tissue and effect of tumor stage on usefulness. Prostate 10: 199–206

    Article  CAS  PubMed  Google Scholar 

  • Cohen MB, Soloway MS, Murphy WM (1994) Sampling of radical prostatectomy specimens. How much is adequate? Am J Clin Pathol 101:250–252

    CAS  PubMed  Google Scholar 

  • Cohen RJ, Glezerson G, Taylor LF, Grundle HAJ, Naude JH (1993) The neuroendocrine cell population of the human prostate gland. J Urol 150:365–368

    CAS  PubMed  Google Scholar 

  • Coleman CN, Beard CJ, Kantoff PW, Gelman R (1993) Rate of relapse following treatment for localized prostate cancer: a critical analysis of retrospective reports. Int J Radiat Oncol Biol Phys 28: 303–313

    Article  Google Scholar 

  • Collins GN, Lloyd SN, Hekir M, McKelvie GB (1993) Multiple transrectal ultrasound-guided prostatic biopsies — True morbidity and patient acceptance. Br J Urol 71:460–463

    Article  CAS  PubMed  Google Scholar 

  • Cooner EH, Mosley BR, Rutherford CL Jr et al. (1990) Prostate cancer detection in a clinical uro-logical practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 143:1146–1154

    CAS  PubMed  Google Scholar 

  • Cooper EH, Robinson MRG, Whelan P et al. (1992) Tumor markers in prostate cancer. Cancer 70: 225–229

    Article  CAS  PubMed  Google Scholar 

  • Corral DA, Balmson RR (1994) Survival of men with clinically localized prostate cancer detected in the eigth decade of life. J Urol 151:1326–1329

    CAS  PubMed  Google Scholar 

  • Cosgrove D (1994) TRUS with contrast agents in carcinoma of the prostate. In: Murphy G, Khoury S, Chatelain C, Denis L (eds) Proceedings of the 4th International Symposium on recent advances in urological cancer. Scientific Communication International, Jersey, pp 131–139

    Google Scholar 

  • Cox RL, Crawford ED (1995) Estrogens in the treatment of prostate cancer. J Urol 154:1991–1998

    Article  CAS  PubMed  Google Scholar 

  • Crawford ED, Eisenberger MA, McLeod DG et al. (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321:419–424

    Article  CAS  PubMed  Google Scholar 

  • Crawford ED, De Antoni EP, Stone NN et al. (1995) Prostate cancer awareness week demonstrates continual value to early detection strategies. J Urol 153:312 A

    Google Scholar 

  • D’Amico AV, Whittington R, Malkonicz SB et al. (1995) A multivariate analysis of clinical and pathological factors that predict for PSA failure after radical prostatectomy for prostate cancer. J Urol 154:131–138

    Article  PubMed  Google Scholar 

  • DeKernion JN, My H, Kaufman JJ et al. (1985) Results of treatment of patients with stage D1 prostatic carcinoma. Urology 26:446–451

    Article  CAS  PubMed  Google Scholar 

  • DeKernion JN, Murphy GD, Priore R et al. (1988) Comparison of flutamide and emcyt in hormone-refractory metastatic prostate cancer. Urology 31:312–317

    Article  CAS  Google Scholar 

  • Demark-Wahnefried W et al. (1992) Body dimension differences in men with or without prostate cancer (Letter), J Natl Cancer Inst 84 (17): 1363–1364

    Article  CAS  PubMed  Google Scholar 

  • Denis L (1995) Commentary on maximal androgen blockade in prostate cancer: A theory to put into practise? Prostate 27:233–240

    Article  CAS  PubMed  Google Scholar 

  • Denis LJ, Murphy GP, Schröder FH (1995) Report on the consensus workshop on screening and global strategy for prostate cancer. Cancer 75:1187–1207

    Article  CAS  PubMed  Google Scholar 

  • Dhom G (1981) Pathologie des Prostata-Carcinoms. Verh Dtsch Ges Urol 32:9–16

    Article  Google Scholar 

  • Dijkman GA, Debruyne FMJ, Fernandez de Moral P et al. Dutch South East Cooperative Urological Group (1994) A phase III randomized trial comparing the efficacy and safety of the 3-month-ly 10.8 mg depot of Zoladex with the monthly 3.6 mg depot in patients with advanced prostate cancer. In: Murphy G, Khoury S, Chatelain C, Denis L (eds) 4th International Symposium on Recent Advances in Urological Cancers. S.C.I. Jersey, pp 305–306

    Google Scholar 

  • Drago IR, Mostofi FK, Lee F (1989) Prostatic intra-epithelial neoplasia: significance and correlation with prostatic specific antigen and transrectal ultrasound. Urology 34 [Suppl]:2–69

    Article  Google Scholar 

  • Duncan W, Catton CN, Warde P et al. (1994) The influence of transurethral resection of prostate on prognosis of patients with adenocarcinoma of the prostate treated by radical radiotherapy. Radiother Oncol 31:41–50

    Article  CAS  PubMed  Google Scholar 

  • Eisenberger MA, Crawford ED, Wolf M et al. (1994) Prognostic factors in stage D2 prostate cancer; important implications for future trials: Results of a cooperative intergroup study (INT 0036). Sem Oncol 21:613–619

    CAS  Google Scholar 

  • Ekreth JT, Miller JI, McBeath RB et al. (1995) PSA obtained under optimal conditions determines extracapsular adenocarcinoma of the prostate. Br J Urol 75:21–25

    Article  Google Scholar 

  • Elhilali M (1994) How to evaluate a patient with elevated PSA between 4–10 ng/ml and benign DRE. In: Murphy G, Khoury S, Châtelain C, Denis L (eds) Proceedings of the 4th International Symposium on recent advances in urological cancer. Scientific Communication International, Jersey, P 127

    Google Scholar 

  • Ellis WJ, Brawer NK (1993) PSA in benign prostatic hyperplasia and prostatic intraepithelial neoplasia. Urol Clin North Am 20:621–625

    CAS  PubMed  Google Scholar 

  • Ellis WJ, Brawer MK (1994) The significance of isoechoic prostatic carcinoma. J Urol 152:2304–2307

    CAS  PubMed  Google Scholar 

  • Engelstein D, Mukamel E, Cytron S, Konichezky M, Slutzki S, Servadio C (1994) A comparison between digitally-guided fine needle aspiration and ultrasound-guided transperineal core needle biopsy of the prostate for the detection of prostate cancer. Br J Urol 74 (2): 210–223

    Article  CAS  PubMed  Google Scholar 

  • Epstein JI, Cho KR, Quinn BD (1990) Relationship of severe dysplasia to stage A (incidental) adenocarcinoma of the prostate. Cancer 65:2321–2327

    Article  CAS  PubMed  Google Scholar 

  • Epstein JI, Carmidiarl M, Partin AW (1993) Is tumor volume independent predictor of progression following radical prostatectomy? Multivariate analysis of 185 clinical stage B adenocarcinomas of prostate with 5 years of followup. J Urol 149:1478–1481

    CAS  PubMed  Google Scholar 

  • Eskelinen M, Lipponen P, Majapuro R, Syrjänen K (1991) Prognostic factors in prostatic adenocarcinoma assessed by means of quantitative histology. Eur Urol 19:274–278

    CAS  PubMed  Google Scholar 

  • Faul P (1991) Die klinische Bedeutung der transrektalen Feinnadelbiopsie und zytologischen Diagnose des Prostatakarzinoms. In: Ackermann R, Altwein JE, Faul P (Hrsg) Aktuelle Therapie des Prostatakarzinoms. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  • Fellows GJ, Clark PB, Beynon LL et al. (1992) Treatment of advanced localised prostate cancer by orchiectomy, radiotherapy, or combined treatment. A Medical Research Council Study. Br J Urol 70:304–309

    CAS  PubMed  Google Scholar 

  • Figueiredo AJC, Seeni K, Anson KM, Furtade AJL, Miller RA (1995) Are transrectal ultrasonically guided biopsies required for the accurate diagnosis of carcinoma of the prostate? Can digitally guided systematic biopsies offer an acceptable alternative? Br J Urol 76:187–191

    Article  CAS  PubMed  Google Scholar 

  • Flanigan RC, Catalopna WJ, Richie JP et al. (1994) Accuracy of digital rectal examination and transrectal ultrasonography in localizing prostate cancer. J Urol 152:1506–1509

    CAS  PubMed  Google Scholar 

  • Forsslund G, Esposti PL, Nilsson B, Zetterberg A (1992) The prognostic significance of nuclear DNA content in prostatic carcinoma. Cancer 69:1432–1439

    Article  CAS  PubMed  Google Scholar 

  • Fossa SD, Dearnaley DP, Law M, Gad J, Newling DWW, Tveter K (1992) Prognostic factors in hormone-resistant progressing cancer of the prostate. Ann Oncol 3:361–366

    CAS  PubMed  Google Scholar 

  • Fox SB, Persad RA, Coleman N, Day CA, Silcocks PB, Collins CC: Prognosic vaclue of c-erbB-2 and epidermal growth factor receptor in stage Ai (Tia) prostatic adenocarcinoma. BR J Urol 74:214–220

    Google Scholar 

  • Franks LM (1974) Biology of the prostate and its tumors. In: Castro JE (ed) The treatment of prostatic hypertrophy and neoplasia. Medical and Technical Publ., London, pp 1–26

    Chapter  Google Scholar 

  • Gee WF, Holtgrewe HL, Albertsen PC, Litwin MS, Manyak MJ, O’Leary PM, Paniter MR (1995) Practice trends in the diagnosis and management of prostate cancer in the US. J Urol 154: 207–208

    Article  CAS  PubMed  Google Scholar 

  • Giovannucci E (1995) Epidemiologic characteristics of prostate cancer. Cancer 75: 1766–1777

    Article  Google Scholar 

  • Gleason DF (1966) Classification of prostatic carcinomas. Cancer Chemother Rep 50:125–128

    CAS  PubMed  Google Scholar 

  • Gleason DF, Mellinger GT, The Veterans Administration Cooperative Urological Research Group (1974) Prediction of prognosis for prostatic adenocarcinoma and combined histological grading and clinical staging. J Urol 11:58–64

    Google Scholar 

  • Goodman CM, Busuttil A, Chisholm GD (1988) Age, size and grade of tumor predict prognosis in incidentally diagnosed carcinoma of the prostate. Br J Urol 62:576–580

    Article  CAS  PubMed  Google Scholar 

  • Grayhack JT, Assimos DG (1983) Prognostic significance of tumor grade and stage in the patient with carcinoma of prostate. Prostate 4:13–31

    Article  CAS  PubMed  Google Scholar 

  • Greene DR, Wheeler TM, Egawa S, Weaver RP, Scardino PT (1991b) Relationship between clinical stage and histological zone of origin in early prostate cancer: Morphometric analysis. Br J Urol 68:499–509

    Article  CAS  PubMed  Google Scholar 

  • Greene DR, Fitzpatrick JM, Scardino PT (1995) Anatomy of the prostate and distribution of early prostate cancer. Sem Surg Oncol 11:9–22

    Article  CAS  Google Scholar 

  • Greenwald P, Kelloff G, Burch-Whitman C, Kramer BS (1995) Chemoprevention. CA Cancer J Clin 45:31–49

    Article  CAS  PubMed  Google Scholar 

  • Griffiths K, Khoury S (1994) Primer on molecular control of prostatic growth. Scientific Communications International, Jersey

    Google Scholar 

  • Grönberg H, Damber JE, Jonsson H, Lenner P (1994) Patient age as a prognostic factor in prostate cancer. J Urol 152:892–895

    PubMed  Google Scholar 

  • Guess HA, Heyse JF, Gormley GJ, Stoner E, Osterling JE (1993) Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia. Urol Clin North Am 20:627–636

    CAS  PubMed  Google Scholar 

  • Guinan P, Bush I, Ray V (1980) The accuracy of the rectal examination in the diagnosis of prostatic carcinoma. N Engl J Med 303:499–503

    Article  CAS  PubMed  Google Scholar 

  • Häggman M, Torre M de la, Brändstedt S, Norlén BJ, Norberg M, Busch C (1994) Pre- and postoperative DNA ploidy patterns correlated to pT-stage, histological grade and tumour volume in total prostatectomy specimens. Scand J Urol Nephrol 28:59–66

    Article  PubMed  Google Scholar 

  • Hammerer P, Huland H (1991 a) Zur Diagnostik des lokalisierten Prostatakarzinoms: Screening und präoperatives Staging. Urologe A 30:378–386

    CAS  PubMed  Google Scholar 

  • Hammerer P, Sparenberg A, Gonnermann D et al. (1991b) Diagnostik von Lymphknotenmetastasen vor radikaler Prostatektomie. Urologe A 30 [Suppl]:A16

    Google Scholar 

  • Hanash KA, Utz DC, Cook EN et al. (1972) Carcinoma of the prostate: a 15-year follow-up. J Urol 107:450–453

    CAS  PubMed  Google Scholar 

  • Harada M, Mostofi FK, Corle FK, Byar DP, Trump BF (1977) Preliminary studies of histological prognosis in cancer of the prostate. Cancer Treat Rep 61:223–225

    CAS  PubMed  Google Scholar 

  • Hedley DW, Friedlander ML, Taylor IW et al. (1983) Method of analysis of cellular DNA content in paraffine embedded pathological material using flow cytrometry. J Histochem Cytochem 31: 1333–1335

    Article  CAS  PubMed  Google Scholar 

  • Herr HW, Kombeith AB, Ofman K (1993) A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy. Cancer 71:1143–1150

    Article  CAS  PubMed  Google Scholar 

  • Hetherington JW, Siddall JK, Cooper EH (1988) Contribution of bone scintigraphy, prostatic acid phosphatase and prostate-specific antigen to the monitoring of prostatic cancer. Eur Urol 14:1–5

    CAS  PubMed  Google Scholar 

  • Hilz H (1995) Molekulare Formen des PSA und ihre klinische Signifikanz. Urologe A 34:275–282

    CAS  PubMed  Google Scholar 

  • Hinman F (1989) Atlas of Urologic Surgery. Saunders, Philadelphia

    Google Scholar 

  • Hodge KK, McNeal JE, Terris MK et al. (1989 a) Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 142:71–75

    CAS  PubMed  Google Scholar 

  • Hodge KK, McNeal JE, Stamey TA (1989 b) Ultrasound guided transrectal core biopsies of the palpably abnormal prostate. J Urol 142:66–70

    CAS  PubMed  Google Scholar 

  • Hölzel D (1995) Prostatakarzinom. Ist die Früherkennung in einer Sackgasse? Dt ärztebl 92: 1353–1363

    Google Scholar 

  • Hölzel D, Altwein JE (1991) Tumoren des Urogenitaltrakts: Klinisch-epidemiologische Fakten. Urologe A 30:134–138

    PubMed  Google Scholar 

  • Hudson MA, Balmson RR, Catalona WJ (1989) Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 142:1011–1017

    CAS  PubMed  Google Scholar 

  • Huland H (1995) Früherkennung des Prostatakarzinoms: Welchen Stellenwert hat die PSA-Bestimmung? TW Urolog Nephrol 7:25–31

    Google Scholar 

  • Humphrey PA, Walther PJ (1993) Adenocarcinoma of the prostate, part II: Tissue prognosticators. Am J Clin Pathol 100:256–269

    CAS  PubMed  Google Scholar 

  • Isaacs WB, Bova GS, Morton RA, Bussemakers MJG, Brooks JD, Ewing CM (1994) Molecular biology of prostate cancer. Sem Oncol 21:514–521

    CAS  Google Scholar 

  • Iversen P (1994) Update of monotherapy trials with new antiandrogen Casodex. In Murphy G, Khury S, Chatelain C, Denis L (eds) 4th International Symposium on Recent Advances in urological cancer. S.C.I. Jersey, pp 317–323

    Google Scholar 

  • Jewett HJ, Bridge RW, Gray GF Jr, Shelley WM (1968) The palpable nodule of prostate cancer results 15 years after radical excision. JAMA 203:403–406

    Article  CAS  PubMed  Google Scholar 

  • Johansson JE, Adami O, Andersson SO et al. (1989) Natural history of localised prostate cancer. A population-based study in 223 untreated patients. Lancet 1:778–803

    Google Scholar 

  • Johansson JE, Andersson SO, Holmberg L et al. (1991) Prognostic factors in progressionfree survival and corrected survival in patients with advanced prostatic cancer: results from a randomized study comprising 150 patients treated with orchiectomy or estrogens. J Urol 146:1327–1333

    CAS  PubMed  Google Scholar 

  • Johansson JE, Adami HO, Andersson SO, Bergström R, Holmberg L, Krusemo JB (1992) High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA 267:2191–2196

    Article  CAS  PubMed  Google Scholar 

  • John EM, Whittemore AS, Wu AH et al. (1995) Vasectomy and prostate cancer: Results from a multiethnic casecontrol study. J Natl Cancer Inst 87 (9): 662–669

    Article  CAS  PubMed  Google Scholar 

  • Jones EC, McNeal J, Bruchovsky N, Jong G de (1990) DNA content in prostatic adenocarcinoma. A flow cytometric study of the predictive value of aneuploidy for tumor volume, percentage Gleason Grade 4 and 5, and lymph node metastases. Cancer 66:752–757

    Article  CAS  PubMed  Google Scholar 

  • Katz AE, De Vries GM, Begg MD et al. (1995) Enhanced reverse transcriptase-polymerase chain reaction for prostate specific antigen as an indicator of true pathologic stage in patients with prostate cancer. Cancer 75 (7): 1642–1648

    Article  CAS  PubMed  Google Scholar 

  • Keetch DW, Catalona WJ, Smith DS (1994) Serial prostatic biopsies in men with persistently elevated serum PSA values. J Urol 151:1571–1574

    CAS  PubMed  Google Scholar 

  • Kleer E, Larson-Keller JJ, Zincke H, Oesterling JE (1993) Ability of preoperative serum prostata-specific antigen value to predict pathologic stage and DNA ploidy: Influence of clinical stage and tumor grade. Urology 41:207–216

    Article  CAS  PubMed  Google Scholar 

  • Konchuba AN, Schellhammer PF, Kolm P, Clements, Wright GL (1993) Deoxyribonucleic acid cytometric analysis of prostate core biopsy specimens: relationship to serum prostate specific antigen and prostatic acid phosphatase, clinical stage and histopathology. J Urol 150:115–119

    CAS  PubMed  Google Scholar 

  • Koutsilieris N, Dupont A, Gomez J, Cusan L et al. (1994) Stratification of stage D2 prostate cancer patients by a disease aggressiveness score and its use in evaluating disease response and outcome to combination hormonal teatment (GnRH-A plus Flutamide). Anticancer Res 14:627–634

    CAS  PubMed  Google Scholar 

  • Krahn MD, Makoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS (1994) Screening for prostate cancer. A decision analytic view. Am Med Ass 272 (10): 773–780

    Article  CAS  Google Scholar 

  • Kühn MW, Weißbach L, Hinke A (1994) Primary therapy of metastatic prostate carcinoma with depot gonadotropin-releasing hormone analogue goserelin versus estramustine phosphate. Urology [Suppl] 43:61–67

    Article  PubMed  Google Scholar 

  • Kuriyama M, Kawada Y (1994) Can PSA predict staging of prostate cancer? In: Murphy G, Khoury S, Chatelain C, Denis L (eds) Proceedings of the 4th (eds) International Symposium on recent advances in urological cancer. Scientific Communication International, Jersey, pp 110–114

    Google Scholar 

  • Kvols LK, Eagan RT, Myers RP (1977) Evaluation of ICRF-159 and hydroxyurea in metastatic prostate cancer a preliminary report. Cancer Treat Rep 61:311–312

    CAS  PubMed  Google Scholar 

  • Lange PH, Ercole CJ, Lightner DJ et al. (1989) The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 141:873

    CAS  PubMed  Google Scholar 

  • Lee C, Sensibar J (1987) Proteins of the rat prostate. II. Synthesis of new proteins in the ventral lobe during castration-induced regression. J Urol 138:903–908

    CAS  PubMed  Google Scholar 

  • Lee E, Torp-Pedersen ST, Littrup PJ et al. (1989 b) Hypoechoic lesions of the prostate: clinical relevance of tumor size, digital rectal examination and prostate specific antigen. Radiology 170:29–32

    CAS  PubMed  Google Scholar 

  • Leistenschneider W, Nagel R (1984) Praxis der Prostatazytologie. Springer, Berlin Heidelberg New York, pp 82–83

    Google Scholar 

  • Li TS, Beling CG (1973) Isolation and characterization of two specific antigens of human seminal plasma. Fertil Steril 24:134

    CAS  PubMed  Google Scholar 

  • Lightner DJ, Lange PH, Reddy PK, Moore L (1990) Prostate specific antigen and local recurrence after radical prostatectomy. J Urol 144:921–926

    CAS  PubMed  Google Scholar 

  • Littrup P, Kane RA, Mettlin CJ et al. (1994) Cost-effective prostate cancer detection: reduction of low-yield biopsies. Cancer 74:3146–3158

    Article  CAS  PubMed  Google Scholar 

  • Lowe BA (1991) Indicental prostate cancer: predictors of progression. In: Altwein JE, Faul P, Schneider W (eds) Incidental carcinoma of the prostate. Springer, Berlin Heidelberg New York Tokyo, pp 99–108

    Chapter  Google Scholar 

  • Lukkarinen O, Kontturi M and the Finnish Zoladex Multicentre Study Group (1994) Comparison of a long-acting LHRH agonist and polyoestradiol phosphate in the treatment of advanced prostatic carcinoma. Scand J Urol Nephrol 28:171–178

    Article  CAS  PubMed  Google Scholar 

  • Lund F, Rasmussen F (1988) Flutamide versus stilboestrol in the management of advanced prostatic cancer. A controlled prospective study. Br J Urol 61:140–142

    Article  CAS  PubMed  Google Scholar 

  • Lynch HT, Larsen AL, Magnuson CW et al. (1966) Prostate carcinoma and multiple primary malignancies; study of a family and 109 consecutive prostate cancer patients. Cancer 19:1891–1897

    Article  CAS  PubMed  Google Scholar 

  • Magnusson A, Fritjofsson A, Norlén BJ et al. (1988) The value of computed tomography and ultrasound in assessment of pelvic lymph node metastases in patients with clinically locally confined carcinoma of the prostate. Scand J Urol Nephrol 22:7–10

    CAS  PubMed  Google Scholar 

  • Lundgren R, Nordle O, Josefsson K, South Sweden Prostate Cancer Study Group (1995) Immediate estrogen or estramustine phosphate therapy versus deferred endocrine treatment in nonmetastatic prostate cancer: a randomized multicenter study with 15 years of followup. J Urol 153:1580–1586

    Article  CAS  PubMed  Google Scholar 

  • McDonnel TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LWK, Hsich JT (1992) Expression of the proto-oncogene bc1–2 in the prostate and its association with emergence of androgen-inde-pendent prostate cancer. Cancer Res 52:6940–6944

    Google Scholar 

  • McDonnel TJ, Troncoso P, Brisbay SM (1992) Expression of the protooncogene bc1–2 in the prostate and its association with the emergence of androgen-independent prostate cancer. Cancer Res 52:6940–6944

    Google Scholar 

  • McMahon RFT, McWilliam LJ, Clarke NW, George NJR (1994) Altered saccharide sequences in two groups of patients with metastatic prostatic carcinoma. Br J Urol 74:80–85

    Article  CAS  PubMed  Google Scholar 

  • McNeal JE, Kindrachuk RA, Freiha FS et al. (1986) Patterns of progression in prostate cancer Lancet 1:60–63

    Article  CAS  PubMed  Google Scholar 

  • Mellinger GT, Gleason D, Bailar J (1967) The histology and prognosis of prostatic cancer. J Urol 97: 331–337

    CAS  PubMed  Google Scholar 

  • Miller GJ, Cygan JM (1994) Morphology of prostate cancer: the effects of multifocality on histological grade, tumor volume and capsule penetration. J Urol 152:1709–1713

    CAS  PubMed  Google Scholar 

  • Miller GJ (1995) What are appropriate pathological standards? Vortrag. Issues and controversies in Prostate Cancer. Whistler (Kanada) 15.–18. 03.

    Google Scholar 

  • Miller J, Horsfall DJ, Skinner JM et al. (1994) Nuclear shape and prognosis following orchiectomy in stage D2 prostate cancer. Prostate 24:306–312

    Article  CAS  PubMed  Google Scholar 

  • Monda JM, Barry MJ, Oesterling JE (1994) Prostate specific antigen cannot distinguish stage T1a (A1) prostate cancer from benign prostatic hyperplasia. J Urol 151(5): 1291–1295

    CAS  PubMed  Google Scholar 

  • Montie JE (1994) Counseling the patient with localized prostate cancer. Urology 43 [Suppl 2]: 36–40

    Article  CAS  PubMed  Google Scholar 

  • Mostofi FK, Davis CJ Jr, Sesterhenn IA (1992) Pathology of carcinoma of the prostate. Cancer 70: 235–253

    Article  CAS  PubMed  Google Scholar 

  • Mostofi FK, Price EB (1973) Tumors of the male genital system. Atlas of tumor pathology. 2nd Ser. Fasc. 8 Armed Forces Institute of Pathology. Washington DC

    Google Scholar 

  • Mostofi FK, Sesterhenn IA, Davis CJ Jr (1976) Problems in pathologic diagnosis of prostatic carcinoma Semin Oncol 3:161–169

    CAS  PubMed  Google Scholar 

  • Mostofi FK, Davis CJ Jr, Sesterhenn IA (1989) Malignant change in hyperplastic prostates: the AFIP experience. Urology 34 [Suppl]: 49–51

    Article  CAS  PubMed  Google Scholar 

  • Mulders PF, Dijkman GA, Fernandez del Moral P, Theenweis AGM, Debruyne FMJ (1990) Analysis of prognostic factors in disseminated prostate cancer. Cancer 65:2758–2761

    Article  CAS  PubMed  Google Scholar 

  • Müller HA, Ackermann R, Frohmüller HGW (1980) The value of perineal punch biopsy in estimating the histological grade of carcinoma of the prostate. The Prostate 1:303–309

    Article  PubMed  Google Scholar 

  • Myers RB, Oelschlager D, Srivastava S, Grizzle WE (1994) Accumulation of the p53 protein occurs more frequently in metastatic than in localized prostatic adenocarcinomas. Prostate 25:243–248

    Article  CAS  PubMed  Google Scholar 

  • Myers RB, Srivastava S, Oelschlager DK, Grizzle WE (1994) Expression of p160 erb B-3 and p185 erb B-2 in prostatic intraepithelial neoplasma and prostatic adenocarcinoma. J Natl Cancer Inst 86:1140–1145

    Article  CAS  PubMed  Google Scholar 

  • Narayan P, Jajodia P, Stein R (1991) Core biopsy instrument in the diagnosis of prostate cancer: superior accuracy to fine needle aspiration. J Urol 145:795–797

    CAS  PubMed  Google Scholar 

  • Norton L, Simon R (1977) Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 61:1307–1317

    CAS  PubMed  Google Scholar 

  • Oesterling JE (1991) Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145:907–923

    CAS  PubMed  Google Scholar 

  • Oesterling JE, Lilja H (1995) Discovery of nuclear forms of serum PSA is a major advancement in prostate cancer detection. AUA Today 8 (2)

    Google Scholar 

  • Oesterling JE, Chan DW, Epstein JL et al. (1988) Prostate specific antigen in the preoperative and postoperative evaluation of localized prostate cancer treated with radical prostatectomy. J Urol 139:766–772

    CAS  PubMed  Google Scholar 

  • Oesterling JE, Rice RC, Glenski WJ, Bergstrahl EJ (1994) Effect of cystoscopy, prostate biopsy, and transurethral resection of prostate on serum prostate-specific antigen concentration. In: Murphy G, Khoury S, Chatelain C, Denis L (eds) Proceedings of the 4th International Symposium on recent advances in urological cancer. Scientific Communication International, Jersey, pp 99–109

    Google Scholar 

  • Ohori M, Wheeler TM, Dunn JK, Stamey TA, Scardino PT (1994) The pathological features and prognosis of prostate cancers detectable with current diagnostic tests. J Urol 152:1714–1720

    CAS  PubMed  Google Scholar 

  • Outwater EK, Petersen RO, Siegelman ES, Gomella LG, Chernesky CE, Mitchell DG (1994) Prostate carcinoma: assessment of diagnostic criteria for capsular penetration on endorectal coil MR images. Radiology 193:333–339

    CAS  PubMed  Google Scholar 

  • Partin AW, Walsh PC (1994) Letter to the editor. J Urol 152:172–173

    CAS  PubMed  Google Scholar 

  • Partin AW, Carter HB, Chan DW et al. (1990) Prostate specific antigen in the staging of localized prostate cancer influence of tumor differentiation, tumor volume and benign prostatic hyperplasia. J Urol 143:474–752

    Google Scholar 

  • Paulson DF (1989) Editorial Comment, J Urol 142:74

    Google Scholar 

  • Pavone-Macaluso M, de Voogt HJ, Viggiano G et al. (1986) Comparison of diethylstilbestrol, cypro-terone acetate and medroxy-progesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the EORTC Urological Group. J Urol 136:624–631

    CAS  PubMed  Google Scholar 

  • Pearson JD, Morrell CH, Landis PK, Carter B, Brant LJ (1994) Mixed-effects regression models for studying the natural history of prostate disease. Stat Med 13:587–601

    Article  CAS  PubMed  Google Scholar 

  • Peller PA, Young DC, Marmaduke DP, Marsh WL, Badalament RA (1995) Sextant prostate biopsies: a histopathologic correlation with radical prostatectomy specimens. Cancer 75:530–538

    Article  CAS  PubMed  Google Scholar 

  • Petrylak DP, Scher HI, Li Z, Myers CE, Geller NL (1992) Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapy. Cancer 70:2870–2878

    Article  CAS  PubMed  Google Scholar 

  • Pisters LL, Troncoso P, Zhan HE, Wei L, Eschenbach AC, Chung LWK (1995) D-met proto-onco-gene expression in benign and malignant human prostate tissues. J Urol 154:293–298

    Article  CAS  PubMed  Google Scholar 

  • Prostate Cancer Trialists’ Collaborative Group (1995) Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 346:265

    Article  Google Scholar 

  • Rana A, Chisholm GD, Khan M, Rashwan HM, Elton RA (1994) Conservative management with symptomatic treatment and delayed hormonal manipulation is justified in men with locally advanced carcinoma of the prostate. Br J Urol 74:637–641

    Article  CAS  PubMed  Google Scholar 

  • Rana A, Chisholm GD, Rashwan HM, Salim A, Merrick MV, Elton RA (1994) Symptomatology of metastatic prostate cancer: Prognostic significance. Br J Urol 73:683–686

    Article  CAS  PubMed  Google Scholar 

  • Reiner WG, Scott WW, Eggleston JC, Walsh PC (1979) Long-term survival after hormonal therapy for stage D prostate cancer. J Urol 122:183–184

    CAS  PubMed  Google Scholar 

  • Reynard JM, Peters TL, Gillatt D (1995) Prostate-specific antigen and prognosis in patients with metastatic prostate cancer: a multivariable analysis of prostate cancer mortality. Br J Urol 75:507–515

    Article  CAS  PubMed  Google Scholar 

  • Riedl CR, Hübner WA, Mossig H, Ogris E, Pflüger H (1995) Prognostic value of prostate specific antigen nadir following orchiectomy in patients with stage C and D prostatic carcinoma.

    Google Scholar 

  • Rifkin MD, Zerhoni EA, Gatsornis CA et al. (1990) Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. N Engl J Med 323:621–626

    Article  CAS  PubMed  Google Scholar 

  • Rinker-Schaeffer CW, Partin AW, Isaacs WB, Coffey DS, Isaacs JT (1994) Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells. Prostate 25:249–265

    Article  CAS  PubMed  Google Scholar 

  • Roach III M, Marquez C, Yuo HS et al (1993) Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 28:33–37

    Article  Google Scholar 

  • Ross RK, Paganini-Hill A, Henderson B (1983) The etiology of prostate cancer: what does epidemiology suggest? Prostate 4:333–344

    Article  CAS  PubMed  Google Scholar 

  • Sadasivan R, Morgan R, Jennings S et al. (1993) Overexpression of her-2/neu may be an indicator of poor prognosis in prostate cancer. J Urol 150:126–131

    CAS  PubMed  Google Scholar 

  • Sakr WA, Haas, GP, Cessin BF, Pouter JE, Crissman JD (1993) The frequency of carcinoma and intraepoithelial neoplasia of prostate in young male patients. J Urol 150:379–389

    CAS  PubMed  Google Scholar 

  • Sandberg AA (1994) Cancer cytogenetics for clinicians. CA Cancer J Clin 44:136–159

    Article  CAS  PubMed  Google Scholar 

  • Sant’Agnese PA di (1995) Neuroendocrine differentiation in prostatic carcinoma. Cancer 75 [Suppl]: 1850–1859

    Article  Google Scholar 

  • Schellhammer PF, Wright GL (1993) Biomolecular and clinical characteristics of PSA and other candidate prostate tumor markers. Urol Clin Am 20:597–606

    CAS  Google Scholar 

  • Schmid HP (1994) The clinically organ-confined adenocarcinoma of the prostate. Fortschr Urol Nephrol 28:59–63

    Google Scholar 

  • Schröder FH (1993) Endocrine therapy for prostate cancer: recent developments and current status. Br J Urol 71:633–640

    Article  PubMed  Google Scholar 

  • Schröder FH (1988) Current concepts in the management of prostatic cancer. Am J Clin Oncol 11 [Suppl I]:51–55

    Google Scholar 

  • Schröder FH, Hop WC, Bloom JH et al. (1985) Grading of prostatic carcinoma. III. Multivariate analysis of prognostic parameters. Prostate 7:13–20

    Article  Google Scholar 

  • Schröder FH, van den Ouden D, Davidson P (1992) The limits of surgery in the cure of prostatic carcinoma. EBU 1 (3): 18–23

    Google Scholar 

  • Schulze H, Willenberg A, Haupt G (1991) Der nukleare Rundheitsfaktor aus prognostischer Parameter beim lokalen Prostatakarzinom. Urologe A 30:19A

    Google Scholar 

  • Scott R, Mutchnik DL, Laskowski TZ et al. (1969) Carcinoma of the prostate in elderly men: incidence, growth characteristics and clinical significance. J Urol 101:602–607

    PubMed  Google Scholar 

  • Scott WW, Boyd HL (1969) Combined hormone control therapy and radical prostatectomy in the treatment of selected cases of advanced carcinoma of the prostate: a retro spectivestudy based upon 25 years of experience. J Urol 101:86–92

    CAS  PubMed  Google Scholar 

  • Scrignoli AR, Walsh PC, Steinberg GD, Steiner MS, Epstein JI (1994) Prognostic factors in men with stage Di prostate cancer: Identification of patients less likely to have prolonged survival after radical prostatectomy. J Urol 152:1077–1081

    Google Scholar 

  • Semjonow A, Brandt B, Oberpenning F, Hertle L (1995) Unterschiedliche Bestimmungsverfahren erschweren die Interpretation des prostataspezifischen Antigens. Urologe A 34:305–315

    Google Scholar 

  • Sensabaugh GF, Crim D (1978) Isolation and characterization of a semen-specific protein from human seminal plasma: a potential new marker for semen identification. J Forens Sci 12:106–115

    Google Scholar 

  • Servadio C, Mukamel E, Kahan E (1984) Carcinoma of the prostate in Israel: some epidemiological and therapeutic considerations. Prostate 5:375

    Article  CAS  PubMed  Google Scholar 

  • Sesterhenn IA, Becker RL, Avallone FA et al. (1991) Image analysis of nucleoli and nucleolar organizing regions in prostate, hyperplasia, intraepithelial neoplasia and prostatic carcinoma. J Uro-gen Pathol 1:61–74

    Google Scholar 

  • Seyden MV, Kantoff PW, Krithivas K et al. (1994) Detection of circulating tumor cells in men with localized prostate cancer. J Clin Oncol 12 (12): 2634–2639

    Google Scholar 

  • Shearer RJ (1991) Prostatic specific antigen. Br J Urol 67:1–5

    Article  CAS  PubMed  Google Scholar 

  • Siddall JK, Cooper EH, Newling DWW, Robinson MRG, Whelan P (1986) An evaluation of the immunochemical measurement of prostatic acid phosphatase and prostatic specific antigen in carcinoma of the prostate. Eur Urol 12:123–130

    CAS  PubMed  Google Scholar 

  • Simons BD, Morrison AS, Young RH, Verhoek-Oftedahl W (1993) The relation of surgery for prostatic hypertrophy to carcinoma of the prostate. Am J Epid 138 (5): 294–300

    CAS  Google Scholar 

  • Singer PA, Tasch ES, Stocking C, Rubin S, Siegler M, Weichselbaum R (1991) Sex or survival: Trackoffs between quality and quantity of life. J Clin Oncol 9:328–334

    CAS  PubMed  Google Scholar 

  • Slonim SM, Cuttino JT Jr, Johnson CJ et al. (1993) Diagnosis of prostatic carcinoma: Value of random transrectal sonographically guided biopsies. AJR 161:1003–1006

    Article  CAS  PubMed  Google Scholar 

  • Smith JA, Cho YH (1990) Management of stage A prostate cancer. Urol Clin N Am 17:769–777

    Google Scholar 

  • Smith JA, Middleton RG (1987) Methods of definitive local therapy. In: Smith JA, Middleton RG (eds) Clinical management of prostatic cancer. Year Book Medical, Chicago, pp 54–84

    Google Scholar 

  • Smith PH (1995) Oestrogens reconsidered. Sem Surg Oncol 11:72–76

    Article  CAS  Google Scholar 

  • Smith PH, Robinson MRG (1995) Renaissance der östrogentherapie beim fortgeschrittenen Prostatakarzinom? Urologe A 34:393–397

    CAS  PubMed  Google Scholar 

  • Stege R, Lundh B, Tribukait B et al. (1990) DNA ploidy and the direct assay of prostatic acid phosphatase and prostatic specific antigen in fine needle aspiration biopsies as diagnostic methods in prostatic carcinoma. J Urol 144:299–302

    CAS  PubMed  Google Scholar 

  • Studer UE (1995) Fortgeschrittenes Prostatakarzinom — welche Hormontherapie wann? Urologe A 34:361–366

    CAS  PubMed  Google Scholar 

  • Tannenbaum M, Tannenbaum S, DeSandis PN et al. (1982) Prognostic significance of nucleolar surface area in prostatic cancer. Urology 19:546–551

    Article  CAS  PubMed  Google Scholar 

  • Taplin ME, Bubley GJ, Shuster TD, Frantz ME et al. (1995) Mutation of the androgen-receptor gene in metastatic androgenindependent prostate cancer. N Engl J Med 332

    Google Scholar 

  • Tempany CM, Zhou X, Zerhouni EA et al. (1994) Staging of prostate cancer: Results of radiology diagnostic oncology group. Project comparison of three MR imaging techniques. Radiology 192: 47–54

    CAS  PubMed  Google Scholar 

  • Terris MK, McNeal J, Stamey TA (1990) Invasion of the seminal vesicle by prostate cancer: detection with transrectal sonography. AJR 155:811–815

    Article  CAS  PubMed  Google Scholar 

  • Thompson IM, Fair WR (1989) Screening for carcinoma of the prostate: efficacy of available screening tests. World J Surg 13:65–70

    Article  CAS  PubMed  Google Scholar 

  • Tinari N, Natoli C, Angelucci D et al. (1993) DNA and S-Phase fraction analysis by flow cytometry in prostate cancer. Cancer 71:1289–1296

    Article  CAS  PubMed  Google Scholar 

  • Tribukait B (1987) Flow cytometry in asssessing the clinical aggressiveness of genito-urinary neoplasms. World J Urol 5:108–122

    Article  Google Scholar 

  • Trinca PJ, Austenfeld MS, Noblo MJ (1994) Study shows no increased risk of prostate cancer in vas-ectomied men. AUA Today 7 (9): 1, 16

    Google Scholar 

  • UICC (1992) TNM Klassifikation maligner Tumoren. 4. Aufl., 2. Revision. Springer, Berlin Heidelberg New York, pp 141–165

    Google Scholar 

  • Vela Navarrete R (1994) Is lymph node dissection still a must before radical prostatectomy? In: Murphy G, Khoury S, Chatelain C, Denis L (eds) 4th International Symposion on Recent Advances in urological cancer. Jersey, pp 195–198

    Google Scholar 

  • Vesalainen S, Lipponen P, Talja M, Syrjänen K (1995 a) Biochemical parameters as prognostic factors in prostatic adenocarcinoma. Acta Oncol 34:53–59

    Article  CAS  PubMed  Google Scholar 

  • Vesalainen S, Lipponen P, Talja M, Kasurinen J, Syrjänen K (1995 b) Nuclear morphometry is of independent prognostic value only in T1 prostatic adenocarcinomas. Prostate 27:110–117

    Article  CAS  PubMed  Google Scholar 

  • Voges G, Wirth M (1995) Wertigkeit minimal invasiver Operationstechniken beim Prostatakarzinom. Urologe B 35:149–152

    Google Scholar 

  • Wald N, Frost C, Chuckle H (1991) Breast cancer screening: the current position. Br Med J 302: 845–846

    Article  CAS  Google Scholar 

  • Walther PJ (1992) Ploidy, grade and tumor area compared as treatment outcome predictors for prostate cancer. AUA Today 5: No 5

    Google Scholar 

  • Wang MC, Valenzuela LA, Murphy GP, Chu TM (1979) Purification of a human prostato specific antigen. Invest Urol 17:159–163

    CAS  PubMed  Google Scholar 

  • Waterbor JW, Bueschen AJ (1995) Prostate cancer screening (United States). Cancer Causes Control 6:267–274

    Article  CAS  PubMed  Google Scholar 

  • Whitmore WF Jr (1990) Locoregional prostatic cancer. Advances in management. Cancer 65: 667–674

    Article  PubMed  Google Scholar 

  • Whittemore AS, Lele C, Friedman GD, Stamey T, Vogelman JH, Orentreich N (1995) PSA as predictor of prostate cancer in black men and white men. J Natl Cancer Inst 87:354–360

    Article  CAS  PubMed  Google Scholar 

  • Wilson JD (1995) The promiscuous receptor. Prostate cancer comes of age. N Engl J Med 332: 1440–1441

    Article  CAS  PubMed  Google Scholar 

  • Wingo PA, Tong T, Bolden S (1995) Cancer statistics 1995. CA Cancer J Clin 45:8–30

    Article  CAS  PubMed  Google Scholar 

  • Wirth MP, Pilarsky C (1995) Die Wertigkeit des prostataspezifischen Antigens bei der Therapiekontrolle des Prostatakarzinoms. Urologe A 34:297–302

    CAS  PubMed  Google Scholar 

  • Wirth MP, Grups J, Frohmüller H (1986) Vergleichende Untersuchungen des prostataspezifischen Antigens und der prostataspezifischen sauren Phosphatase in der Diagnostik und Verlaufskontrolle des Prostata-Carcinoms. Verh Deutsch Ges Urol 4:75–76

    Google Scholar 

  • Wirth MP, Manseck A, Frohmüller H (1990) Wertigkeit des prostatspezifischen Antigens (PSA) und der prostataspezifischen sauren Phosphatase in der Früherkennung des Prostata-Carcinoms. Urologe A 29:10

    Google Scholar 

  • Wirth MP, Müller HA, Manseck A, Müller J, Frohmüller HGW (1991) Value of nuclear DNA ploidy patterns in patients with prostate cancer after radical prostatectomy. Eur Urol 20:248–252

    CAS  PubMed  Google Scholar 

  • Woolf CM (1960) An investigation of the familiar aspects of carcinoma of the prostate. Cancer 13: 739–743

    Article  CAS  PubMed  Google Scholar 

  • Wolman SR, Macoska JA, Micale MA, Sakr WA (1992) An approach to definition of genetic alterations in prostate cancer. Diagn Mol Pathol 1 (3): 192–199

    CAS  PubMed  Google Scholar 

  • Wood DP (1995) The molecular staging of prostate cancer. Sem Urol 13:96–102

    Google Scholar 

  • Yamashita K, Denno K, Ueda T et al. (1993) Prognostic significance of bone metastases in patients with metastatic prostate cancer. Cancer 71:1297–1302

    Article  CAS  PubMed  Google Scholar 

  • Yu H, Diamandis EP (1995) Measurement of serum prostate specific antigen levels in women an in prostatectomized men with an ultrasensitive immunoassay technique. J Urol 153:1004–1008

    Article  CAS  PubMed  Google Scholar 

  • Zagars GK, Eschenbach AC, Ayala AG (1993 b) Prognostic factors in prostatic cancer: analysis of 874 patients treated with radiation therapy. Cancer 72:1709–1725

    Article  CAS  PubMed  Google Scholar 

  • Zagars GK, Eschenbach AC v (1993) Prostate specific antigen: An important marker for prostate cancer treated by external beam radiotherapy. Cancer 72:538–548

    Article  CAS  PubMed  Google Scholar 

  • Zagars GK, Sands ME, Pollack A, Eschenbach AC v (1994) Early androgen ablation for stage D1 (N1 to N3, Mo) prostate cancer: prognostic variables and outcome. J Urol 151:1330–1333

    CAS  PubMed  Google Scholar 

  • Zincke H, Bergstralh EJ, Larson-Keller JJ et al. (1992) Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment evidence for favorable survival in patients with DNA diploid tumors. Cancer 70:311–323

    Article  CAS  PubMed  Google Scholar 

  • Ackermann R, Frohmüller HG (1983) Complications and morbidity following radical prostatectomy. World J Urol 1:62–67

    Article  Google Scholar 

  • Adolfsson J, Steineck G, Whitmore WF (1993) Recent results of management of palpable clinically localized prostate cancer. Cancer 72:310–322

    Article  CAS  PubMed  Google Scholar 

  • Albers DD, Faulkner KK, Cheatham WN et al. (1973) Surgical anatomy of the pubovesical (puboprostatic) ligaments. J Urol 109:388–392

    CAS  PubMed  Google Scholar 

  • Andriole GL, Smith DS, Rao G et al. (1994) Early complications of contemporary anatomical radical retropubic prostatectomy. J Urol 152:1858–1860

    CAS  PubMed  Google Scholar 

  • Anscher MS, Robertson CN, Prosnitz R (1995) Adjuvant radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate: ten years update. Int J Radiat Oncol Biol Phys 33:37–43

    Article  CAS  PubMed  Google Scholar 

  • Asbell SO, Krall JM, Pilepich MV et al. (1988) Elective pelvic irradiation in stage A2, B carcinoma of the prostate: A analysis of RTOG 77–06. Int J Radiat Oncol Biol Phys 15:1307

    Article  CAS  PubMed  Google Scholar 

  • Aus G, Hugosson J, Norlèn L (1995) Long-term survival and mortality in prostate cancer treated with noncurative intent. J Urol 154:460–465

    Article  CAS  PubMed  Google Scholar 

  • Babaian RJ, Kojima M, Saitoh M et al. (1995) Detection of residual prostate cancer after external radiotherapy. Role of prostate specific antigen and transrectal ultrasonography. Cancer 75: 2153–2158

    Article  CAS  PubMed  Google Scholar 

  • Babcock JR, Grayhack JT (1979) Morbidity of pelvic lymphadenectomy. Urology 13:483–486

    Article  CAS  PubMed  Google Scholar 

  • Bagshaw MA (1980) External Radiation therapy of carcinoma of the prostate. Cancer 45:1912

    CAS  PubMed  Google Scholar 

  • Bagshaw MA (1985) Potential for radiotherapy alone in prostatic cancer. Cancer 55:2079–2085

    Article  CAS  PubMed  Google Scholar 

  • Bagshaw MA, Kaplan HS, Sagerman RH (1965) Linear accelerator supervoltage radiotherapy. VII. Carcinoma of the prostate. Radiology 85:121

    CAS  PubMed  Google Scholar 

  • Bandhauer K, Senn E (1987) Radikale retropubische Prostatektomie nach transurethraler Resektion. Verh Ber Dtsch Ges Urol 38:90–91

    Google Scholar 

  • Bass RB, Barrett DM (1980) Radical retropubic prostatectomy after transurethral resection. J Urol 124:495–497

    PubMed  Google Scholar 

  • Beck JR, Kattan MW, Miles BJ (1994) A critique of the decision analysis for clinically localized prostate cancer. J Urol 152:1894–1899

    CAS  PubMed  Google Scholar 

  • Ben-Josef E, Porter AT (1995) Radiotherapy of T1c prostate cancer. Semin Urol Oncol 13:191–196

    CAS  PubMed  Google Scholar 

  • Berger RE, Ireton R (1983) Combined infrapubic and retropubic ligation of the dorsal vein of penis during radical retropubic surgery. J Urol 130:1107–1109

    CAS  PubMed  Google Scholar 

  • Bonnand P, Dufour B, Couvelaire R et al. (1977) Les prostatectomies totales et les prostatotrigonectomies „de nécessité” dans le traitement du cancer prostatique. J Urol Nephrol 77:185–190

    Google Scholar 

  • Boxer RJ, Kaufmann JJ, Goodwin WE (1977) Radical prostatectomy for carcinoma of the prostate: 1951–1976. A review of 329 patients. J Urol 117:208–213

    CAS  PubMed  Google Scholar 

  • Brawer MK, Ellis WJ, Bigler SA et al. (1993) The importance of isoechoic lesions on transrectal ultrasonographic prostate needle biopsy. J Ultrasound Med 12:69A

    Google Scholar 

  • Brendler CB (1995) Characteristics of prostate cancer found with early detection regimens. Urology [Suppl A]: 71–76

    Google Scholar 

  • Bressel M (1989) Radikale retropubische Prostatektomie (RRP). In: Sommerkamp H, Altwein JE (Hrsg) Prostatakarzinom — Spektrum der kurativen Therapie. Karger, Basel, S. 146–173

    Google Scholar 

  • Bundrick WS, Culkin DJ, Mata JA et al. (1993) Evaluation of the current incidence of nodal metastasis from prostate cancer. J Surg Oncol 52:269–271

    Article  CAS  PubMed  Google Scholar 

  • Budach V (1991) The role of fast neutrons in radiooncology — a critical appraisal. Strahlenther Onkol 157:33–40

    Google Scholar 

  • Campbell BW (1958) Total prostatectomy with preliminary ligation of vascular pedicles. J Urol 81: 464–467

    Google Scholar 

  • Campbell JL, Thomely MW, Parsons RL (1963) Complications of radical prostatectomy. J Urol 89: 253–254

    CAS  PubMed  Google Scholar 

  • Cantrell BB, Deklerk DP, Eggleston JC et al. (1981) Pathological factors that influence prognosis in stage A prostatic cancer: the influence of extent versus grade. J Urol 125:516–520

    CAS  PubMed  Google Scholar 

  • Catalona WJ (1994) Expectant management and the natural history of localized prostate cancer. J Urol 152:1751–1752

    CAS  PubMed  Google Scholar 

  • Catalona WJ, Bigg SW (1990) Nerve-sparing radical prostatectomy: evaluation of results after 250 patients. J Urol 143:538–544

    CAS  PubMed  Google Scholar 

  • Catalona WJ, Miller DR, Kavoussi LE (1988) Intermediate-term surcical results in clinically un-derstaged prostate cancer patients following radical prostatectomy. J Urol 140:540–453

    CAS  PubMed  Google Scholar 

  • Chinn DM, Holland J, Crownover RL, Roach M 3rd (1995) Potency following high-dose three-dimensional conformai radiotherapy and the impact of prior major urological surgical procedures in patients treated for prostate cancer. Int J Rad Oncol Biol Phys 33:15–22

    Article  CAS  Google Scholar 

  • Chodak GW, Thisted RA, Gerber GS et al. (1994) Results of conservative management of clinically localized prostate cancer. N Engl J Med 330:242–248

    Article  CAS  PubMed  Google Scholar 

  • Constantinon CE, Freiha FS (1992) Impact of radical prostatectomy on the characteristic of bladder and urethra. J Urol 148:1215–1218

    Google Scholar 

  • Critz FA, Tarlton RS, Holladay DA (1995) Prostate specific antigen-monitored combination radiotherapy for patients with prostate cancer. 1–125 implant followed by external-beam radiation. Cancer 75:2383–2391

    Article  CAS  PubMed  Google Scholar 

  • Crook JM, Perry GA, Robertson S, Esche BA (1995) Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients. Urology 45:624–631

    Article  CAS  PubMed  Google Scholar 

  • Danella JF, DeKernion JB, Smith RB, Steckel J (1993) The contemporary incidence of lymph node metastases in prostate cancer: implications for laparoscopic lymph node dissection. J Urol 149: 1488

    CAS  PubMed  Google Scholar 

  • DeKernion JM, My H, Kaufmann JJ et al. (1985) Results of treatment of patients with stage D1 prostatic carcinoma. Urology 26:446–451

    Article  CAS  PubMed  Google Scholar 

  • Del Regato JA (1967) Radiotherapy in the conservative treatment of operable and locally inoperable carcinoma of the prostate. Radiology 88:761

    PubMed  Google Scholar 

  • Dewit L, Ang KK, van der Schueren E (1983) Acute side effects and late complications after radiotherapy of localized carcinoma of the prostate. Cancer Treat Rev 10:79

    Article  CAS  PubMed  Google Scholar 

  • Dillioglugil Æ, Miles BJ, Scardino PT (1995) Current controversies in the managment of localised prostate cancer. Eur Urol 28:85–101

    CAS  PubMed  Google Scholar 

  • Elder JS, Gibbons RP, Correa RJ et al. (1984) Morbidity of radical perineal prostatectomy following transurethral resection of the prostate. J Urol 132:55–57

    CAS  PubMed  Google Scholar 

  • Engeler CE, Wasserman NF, Zhang G (1992) Preoperative assessment of prostatic carcinoma by computerized tomography. Weaknesses and new perspectives. Urology 40:346–350

    Article  CAS  PubMed  Google Scholar 

  • Epstein BE, Hanks GE (1993) Radiation therapy techniques and dose selection in the treatment of prostate cancer. Semin Radiat Oncol 3:179–186

    Article  PubMed  Google Scholar 

  • Epstein JI (1990) Evaluation of radical prostatectomy capsular margins of resection. The significance of margins designated as negative, closely approaching, and positive. Am J Surg Pathol 14: 626–632

    Article  CAS  PubMed  Google Scholar 

  • Epstein JI, Walsh PC, Eggleston JC (1986) Prognosis of untreated state A 1 prostate carcinoma: a study of 94 cases with extended follow-up. J Urol 136:837–839

    CAS  PubMed  Google Scholar 

  • Epstein JI, Oesterling JE, Walsh PC (1988) The volume and anatomical location of residual tumor in radical prostatectomy specimens removed for stage A1 prostate cancer. J Urol 139:975–979

    CAS  PubMed  Google Scholar 

  • Epstein JI, Walsh PC, Brendler CB (1994) Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stages T1a and T1b) and on needle biopsy (stage T1c). J Urol 152:1721–1729

    CAS  PubMed  Google Scholar 

  • Fair WR, Aprikian AG, Cohen D et al. (1993) Use of neoadjuvant androgen deprivation therapy in clinically localized prostate cancer. Clin Invest Med 16:516–522

    CAS  PubMed  Google Scholar 

  • Flanagan WF, Webster GD, Brown MW et al. (1985) Lumbosacral plexus stretch injury following the use of modified lithotomy position. J Urol 134:567–568

    CAS  PubMed  Google Scholar 

  • Fleming C, Wasson JH, Albertsen PC et al. (1993) A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team. JAMA 269:2650–2558

    Article  CAS  PubMed  Google Scholar 

  • Fowler JE Jr, Braswell NT, Pandey P, Seaver L (1995) Experience with radical prostatectomy and radiation therapy for localized prostate cancer at a Veterans Affairs Medical Center. J Urol 153: 1026–1031

    Article  PubMed  Google Scholar 

  • Franke HD, Schmidt R (1985) Clinical results with fast neutrons (DT, 14 MeV). Radiat Med 3:151–160

    CAS  PubMed  Google Scholar 

  • Frohmüller H, Theiss M, Manseck A, Wirth MP (1995) Survival and quality of life of patients with stage D1 (T1–3 pN1–2) prostate cancer. Eur Urol 27:202–206

    PubMed  Google Scholar 

  • Frohmüller H, Theiss M, Wirth MP (1991) Radical prostatectomy for carcinoma of the prostate: Long-term follow-up of 115 patients. Eur Urol 19:279–283

    PubMed  Google Scholar 

  • Frohmüller H, Theiss M, Wirth MP et al. (1995) 15-Jahres-Ergebnisse der radikalen Prostatektomie. Urologe A 34:225–230

    PubMed  Google Scholar 

  • Gerber GS, Chodak GW (1991) Routine screening for cancer of the prostate. J Natl Cancer Inst 83: 329–335

    Article  CAS  PubMed  Google Scholar 

  • Gibbons RP, Cole S, Richardson RG et al. (1986) Adjuvant radiotherapy following radical prostatectomy: results and complications. J Urol 135:65–68

    CAS  PubMed  Google Scholar 

  • Gil-Vernet JM, Gutierrez de Pozo R, Caretero P et al. (1988) Urogenital diaphragm raising maneuvre. J Urol 140:555–558

    CAS  PubMed  Google Scholar 

  • Hammerer P, Hübner D, Gonnermann D, Huland H (1995) Perioperative und postoperative Komplikationen der pelvinen Lymphadenektomie und radikalen Prostatektomie bei 320 konsekutiven Patienten. Urologe [A] 34:334–342

    CAS  Google Scholar 

  • Hanks GE, Leibel SA, Krall JM, Kramer S (1985) Patterns of care studies: Dose response of observations for local control of adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 11:153–157

    Article  CAS  PubMed  Google Scholar 

  • Haraf DJ, Rubin SJ, Sweeney P et al. (1995) Photon neutron mixed beam radiotherapy of locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 33:3–14

    Article  CAS  PubMed  Google Scholar 

  • Hauri D, Heinzelmann M, Konstatinidis K (1988) Radical prostatectomy in case of prostatic carcinoma: the problem of postoperative urinary incontinence. Urol Int 43:257–264

    Article  CAS  PubMed  Google Scholar 

  • Helgason AR, Fredrikson M, Adolfsson J, Steineck G (1995) Decreased sexual capacity after external radiation therapy for prostate cancer impairs quality of life. Int J Radiat Oncol Biol Phys 32: 33–39

    Article  CAS  PubMed  Google Scholar 

  • Hochstetler JA, Kreder KJ, Brown CK, Loening SA (1995) Survival of patients with localized prostate cancer treated with percutaneous transperineal placement of radioactive gold seeds: stages A 2, B, and C. Prostate 26:316–324

    Article  CAS  PubMed  Google Scholar 

  • Hodge KK, McNeal JE, Terris MK et al. (1989) Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 142:71–75

    CAS  PubMed  Google Scholar 

  • Hodge KK, McNeal JE, Stamey TA et al. (1989) Ultrasound guided transrectal core biopsies of the palpably abnormal prostate. J Urol 142:66–70

    CAS  PubMed  Google Scholar 

  • Hudson HC, Howland RJ (1972) Radical retropubic prostatectomy for cancer of the prostate. J Urol 108:944–947

    CAS  PubMed  Google Scholar 

  • Igel TC, Barrett DM, Segure JW et al. (1987) Perioperative and postoperative complications from bilateral pelvic lymphadenectomy and radical retropubic prostatectomy. J Urol 137:1189–1191

    CAS  PubMed  Google Scholar 

  • Irwin MB, Trapasso JG (1994) Identification of insignificant prostate cancers: Analysis of preoperative parameters. Urology 44:862–868

    Article  CAS  PubMed  Google Scholar 

  • Israeli RS, Miller WH, Su SL et al. (1994) Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: Comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. Cancer Res 54:6306–6310

    CAS  PubMed  Google Scholar 

  • Jewett HJ (1975) The present status of radical prostatectomy for stages A and B prostatic cancer. Urol Clin North Am 2:105–124

    CAS  PubMed  Google Scholar 

  • Jewett HR (1972) Radical perineal prostatectomy in the treatment of carcinoma of the prostate. In: Scott R (ed) Current controverses in urologic management. Saunders, Philadelphia, pp 82–95

    Google Scholar 

  • Johansson JE (1994) Expectant management of early stage prostatic cancer: Swedish experience. J Urol 152:1753–1756

    CAS  PubMed  Google Scholar 

  • Jones EC (1990) Resection margin status in radical retropubic prostatectomy specimen: relationship to type of operation, tumor size, tumor grade and local tumor extension. J Urol 144:89–93

    CAS  PubMed  Google Scholar 

  • Kabalin JN, Hodge KK, McNeal JE et al. (1989) Identification of residual cancer in the prostate following radiation therapy: role of transrectal ultrasound guided biopsy and prostate specific antigen. J Urol 142:326

    CAS  PubMed  Google Scholar 

  • Kadesky KT, Djavan BR, Klopukh BV et al. (1994) Gleason grades from prostate biopsies obtained with 18-G Biopty-gun-needles poorly predict pathological grades of prostatectomy specimen. Presented at the Annual Meeting, American Urological Association, South Central Section, Vancouver, British Columbia, August 27–31

    Google Scholar 

  • Kaplan ID, Bagshaw MA, Cox CA et al. (1991) Radiotherapy for incidental adenocarcinoma of the prostate. In: Altwein JE, Faul P, Schneider W (eds) Incidental carcinoma of the prostate. Springer, Berlin Heidelberg New York Tokyo, pp 167–178

    Chapter  Google Scholar 

  • Kaye KW, Olson DJ, Payne JT (1995) Detailed preliminary analysis of 125 iodine implantation for localized postate cancer using percutaneous approach. J Urol 153:1020–1025

    Article  CAS  PubMed  Google Scholar 

  • Keuler FU, Leitenberger A, Altwein JE (1990) Ist die Verschiebung der Altersbegrenzung der radikalen Prostatektomie gerechtfertigt? Aktuelle Urol 21:245–250

    Article  Google Scholar 

  • Kier R, Wain S, Troiano R (1993) Fast spin-echo MR images of the pelvis obtained with a pha-sed-array coil: value in localizing and staging prostatic carcinoma. Am J Roentgenol 161: 601–606

    Article  CAS  Google Scholar 

  • Killian GS, Yang N, Emrich LJ et al. (1985) Prognostic importance of prostate-specific antigen for monitoring patients with stage B 2 to D1 prostate cancer. Cancer Res 45:886

    CAS  PubMed  Google Scholar 

  • Kopecky AA, Laskowsky TZ, Scott R (1970) Radical retropubic prostatectomy in the treatment of prostatic carcinoma. J Urol 103:641–644

    CAS  PubMed  Google Scholar 

  • Krieger JN, Krall JM, Laramore GE et al. (1989) Fast neutron radiotherapy for locally advanced prostate cancer. Update of a past trial and future research directions. Urology 34:1–9

    Article  CAS  PubMed  Google Scholar 

  • Kröpfel D, Krause R, Härtung R et al. (1988) A method to avoid lymphoceles in heparinised patients. J Urol 139:168

    Google Scholar 

  • Labrie F, Dupont A, Cusan L et al. (1993) Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. Clin Invest Med 16:499–509

    CAS  PubMed  Google Scholar 

  • Lange PH, Moon TD, Narayan P et al. (1986) Radiation therapy as adjuvant treatment after radical prostatectomy: patient tolerance and preliminary results. J Urol 136:45–49

    CAS  PubMed  Google Scholar 

  • Lange PH, Reddy PK (1987) Technical nuances and surgical results of radical retropubic prostatectomy in 150 patients. J Urol 138:348–352

    CAS  PubMed  Google Scholar 

  • Lawton CA, Won M, Pilepich MV et al. (1991) Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: Analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys 21:935–939

    Article  CAS  PubMed  Google Scholar 

  • Lehmann TH, Kirchheim D, Braun G et al. (1968) An evaluation of radical prostatectomy for incidentally diagnosed carcinoma of the prostate. J Urol 99:646–650

    Google Scholar 

  • Leibel SA, Zelefsky MJ, Kutcher GJ et al. (1994) Three-dimensional conformai radiation therapy in localized carcinoma of the prostate: interim report of a phase 1 dose-escalation study. J Urol 152: 1792–1798

    CAS  PubMed  Google Scholar 

  • Lerner SE, Fleischmann J, Taub HC et al. (1994) Combined laparoscopic pelvic lymph node dissection and modified belt radical perineal prostatectomy for localized prostatic adenocarcinoma. 493–498

    Google Scholar 

  • Lindner A, DeKernion JB, Smith RB et al. (1983) Risk of urinary incontinence following radical prostatectomy. J Urol 129:1007–1008

    CAS  PubMed  Google Scholar 

  • Livne PM, Huben RP, Wolf RM et al. (1986) Early complications of combined pelvic lymphadenectomy versus lymphadenectomy alone. Prostate 8:313–318

    Article  CAS  PubMed  Google Scholar 

  • Mador DR, Huben RP, Wajsman Z et al. (1985) Salvage surgery following radical radiotherapy for adonocarcinoma of the prostate. J Urol 133:58–60

    CAS  PubMed  Google Scholar 

  • Manseck A, Wirth M, Theiss M, Frohmüller H (1994) Radical prostatectomy in patients with incidental prostate carcinoma. Urol Int 53:196–208

    Article  CAS  PubMed  Google Scholar 

  • McCullough DL, McLaughlin AP, Gittes RF (1977) Morbidity of pelvic lymphadenectomy and radical prostatectomy for prostatic cancer. J Urol 117:206–207

    CAS  PubMed  Google Scholar 

  • McNeil BJ, Pauker SG, Sox HC et al. (1982) On the elicitation of preferences for alternative therapies: New Engl J Med 306:1259

    Article  CAS  PubMed  Google Scholar 

  • Middelton AW (1987) Radical prostatectomy of carcinoma in men more than 69 years old. J Urol 138:185–188

    Google Scholar 

  • Moralez P, Littman R, Golinbu M (1973) Transpubic surgery: a new approach to difficult operations. J Urol 110:564–570

    Google Scholar 

  • Morse RM, Spirnak JP, Resnik MI (1988) Iatrogenic colon and rectal injuries associated with uro-logical intervention: report of 14 patients. J Urol 140:101–103

    CAS  PubMed  Google Scholar 

  • Murphy GP, Mettlin C, Menck H et al. (1994) National patterns of prostate cancer treatment by radical prostatectomy: results of a surveiley by the american college of surgeons commission on cancer. J Urol 152:1817–1819

    CAS  PubMed  Google Scholar 

  • Myers RP, Goellner JR, Cahill DR (1987) Prostate shape, external striated urethral Sphinkter and radical prostatectomy: the apical dissection. J Urol 138:543–550

    CAS  PubMed  Google Scholar 

  • Nag S, Scaperoth DD, Badalament R, Hall SA, Burgers J (1995) Transperineal palladium 103 prostate brachytherapy: analysis of morbidity and seed migration. Urology 45:87–92

    Article  CAS  PubMed  Google Scholar 

  • Neerhut GJ, Wheeler T, Cantini M et al. (1988) Salvage radical prostatectomy for radio recurrent adenocarcinoma of the prostate. J Urol 140:544–549

    CAS  PubMed  Google Scholar 

  • Nichols RT, Barry JM, Hodges CV (1977) The morbidity of radical prostatectomy for multifocal stage I prostatic adenocarcinoma. J Urol 117:83–84

    CAS  PubMed  Google Scholar 

  • O’Donnell PD, Finau BJ (1989) Continence following nerve-sparing radical prostatectomy. J Urol 142:1227–1228

    PubMed  Google Scholar 

  • Oesterling JE, Martin SK, Bergstralh EJ et al. (1993) The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 269:57–60

    Article  CAS  PubMed  Google Scholar 

  • Oesterling JE, Chan DW, Epstein JL et al. (1988) Prostate specific antigen in the preoperative and postoperative evaluation of localized prostate cancer treated with radical prostatectomy. J Urol 139:766–772

    CAS  PubMed  Google Scholar 

  • Ohori M, Goad JR, Wheeler TM et al. (1994) Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 152:1843–1849

    CAS  PubMed  Google Scholar 

  • Ohori M, Wheeler TM, Dunn JK et al. (1994) The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol 152:1714–1720

    CAS  PubMed  Google Scholar 

  • Olsson CA (1987) Management of localized adenocarcinoma of the prostate. In: Bruce AW, Trachtenberg J (eds) Adenocarcinoma of the prostate. Springer, London, pp 129–144

    Chapter  Google Scholar 

  • Outwater EK, Mitchell DG, Vinitski S (1994) Abdominal MR imaging: evaluation of a fast spin-echo sequence. Radiology 190:425–429

    CAS  PubMed  Google Scholar 

  • Oyen RH, VanPoppel HP, Ameye FE et al. (1994) Lymph node staging of localized prostatic carcinoma with CT and CT-guided fine-needle aspiration biopsy: prospective study of 285 patients. Radiology 190:315–322

    CAS  PubMed  Google Scholar 

  • Palken M, Cobb OE, Warren BH et al. (1990) Prostate cancer: Correlation of digital rectal examination, transrectal ultrasound and prostate specific antigen levels with tumor volumes in radical prostatectomy specimens. J Urol 143:1155–1162

    CAS  PubMed  Google Scholar 

  • Parra RO, Boullier JA, Rauscher JA, Cummings JM (1994) The value of laparoscopic lymphadenectomy in conjunction with radical perineal or retropubic prostatectomy. J Urol 151:1599–1602

    CAS  PubMed  Google Scholar 

  • Parry WL (1983) Radical perineal prostatovesiculectomy. In: Glenn JF (ed) Urologie surgery. Lippin-cott, Philadelphia, pp 960–967

    Google Scholar 

  • Partin AW, Pound CR, Clemens JQ et al. (1993) Serum PSA after anatomic radical prostatectomy. Urol Clin North Am 20:713

    CAS  PubMed  Google Scholar 

  • Paulson DF (1988) Diagnosis of metastatic or locally recurrent prostatic cancer. In: McCullough DL (ed) Difficult diagnosis in urology. Churchill Livingstone, New York, p 277

    Google Scholar 

  • Paulson DF (1980) The prognostic role of lymphadenectomy in adenocarcinoma of the prostate. Urol Clin North Am 7:615–629

    CAS  PubMed  Google Scholar 

  • Paulson DF, Robertson CN (1991) The relevance of stage A prostatic adenocarcinoma. J Urol 140: 535–539

    Google Scholar 

  • Paulson DF, Moul JW, Walther PJ (1990) Radical prostatectomy for clinical stage T1–2 N2 Mo prostatic adenocarinoma: Long-term results. J Urol 144:1180–1184

    CAS  PubMed  Google Scholar 

  • Paulson DF (1994) Impact of radical prostatectomy in the management of clinically localized disease. J Urol 152:1826–1830

    CAS  PubMed  Google Scholar 

  • Paulsson DF (1988) Diagnosis of metastatic or locally recurrent prostatic cancer. In: McCullough DL (ed) Difficult diagnosis in urology. Churchill Livingstone, New York, p 277

    Google Scholar 

  • Perez CA, Lee HK, Georgiou A et al. (1993) Technical and tumor-related factors affecting outcome of definitive irradiation for localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 26: 581–591

    Article  CAS  PubMed  Google Scholar 

  • Peter CA, Walsh PC (1985) Blood transfilsion and anesthetic practices in radical retropubic prostatectomy. J Urol 134:81–83

    Google Scholar 

  • Peters PC (1988) Complications of radical prostatectomy and lymphadenectomy. Urol Clin North Am 15:219–221

    CAS  PubMed  Google Scholar 

  • Pilepich MV, Perez CA, Walz BJ, Zivnuska FR (1981) Complications of definitive radiotherapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 7:1341

    Article  CAS  PubMed  Google Scholar 

  • Pilepich MV, Walz BJ, Baglan RJ (1984) Postoperative irradiation in carcinoma of the prostate. Int J Radiat Oncol Biol Phys 10:1869–1873

    Article  CAS  PubMed  Google Scholar 

  • Pistenma DA, Bagshaw MA, Feiha FS (1979) Extended field radationtherapy for prostatic adenocarcinoma: status report of a limited prospective trial. In: Johnson DE, Samuels ML (eds) Cancer of the Genitourinary Tract. Raven Press New York, S. 229–247

    Google Scholar 

  • Reiner WG, Walsh PC (1979) An anatomical approach to the surgical management of the dorsal vein and Santorini’s plexus during radical retropubic surgery. J Urol 121:198–200

    CAS  PubMed  Google Scholar 

  • Rifkin MD, Zerhoni EA, Gatsornis CA et al. (1990) Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. N Engl J Med 323:621–626

    Article  CAS  PubMed  Google Scholar 

  • Rudy DC, Woodside JR, Crawford ED (1984) Urodynamic evaluation of incontinence in patient undergoing modified Campbell radical prostatectomy: a prospective study. J Urol 132:708–712

    CAS  PubMed  Google Scholar 

  • Sack H, Nosbüsch H, Stützer H (1987) Radiotherapy of prostate carcinoma: Results of treatment and complications. Radiother Oncol 19:7–15

    Article  Google Scholar 

  • Scardino PT, Wheeler TM (1988) Local control of prostate cancer with radiotherapy: frequency and prognostic significance of positive results of postirradiation prostate biopsy. Natl Cancer Inst Monogr 7:95

    Google Scholar 

  • Schmid HP, Ferrari MK, Stamey TA (1994) Long-term follow-up of serum prostate-specific antigen after radiotherapy of prostatic carcinoma. Helv Chir Acta 60:1101–1105

    CAS  PubMed  Google Scholar 

  • Schmid HP, Moch H, Hering F et al. (1994) Neuroendokrine Marker als Prognosefaktoren beim radikal operierten Prostatakarzinom. Urologe A 33:138

    Google Scholar 

  • Schulman CC, Sassine AM (1993) Neoadjuvant hormonal treatment of locally advanced prostate cancer: does it make sense? Curr Opin Urol 3:394–399

    Article  Google Scholar 

  • Scott WW, Boyd HL (1969) Combined hormon control therapy and radical prostatectomy in the treatment of selected cases of advanced carcinoma of the prostate: a retrospective study based upon 25 years of experience. J Urol 101:86–92

    CAS  PubMed  Google Scholar 

  • Shipley WU, Verhey LJ, Munzenrider JE et al. (1995) Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformai protons compared with conventional dose irradiation using photons alone. J Radiat Oncol Biol Phys 32:3–12

    Article  CAS  Google Scholar 

  • Scaletscky R, Koch MO, Eckstein CW et al. (1994) Tumor volume and stage in carcinoma of the prostate detected by elevations in prostate specific antigen. J Urol 152:129–131

    CAS  PubMed  Google Scholar 

  • Smith AM, Veenemar RJ (1972) Management of rectal injury and rectourethral fistulas following radical retropubic prostatectomy. Urology 108:778–779

    CAS  Google Scholar 

  • Smith JA (1995) Stage T1c Prostate cancer: Perspectives on clinical management. Semin Urol Onc 13:238–244

    Google Scholar 

  • Smith JA, Cho YH (1990) Managment of stage A prostate cancer. Urol Clin North Am 17:769–777

    PubMed  Google Scholar 

  • Smith JA, Middleton RG (1987) Methods of definitive local therapy. In: Smith JA, Middleton RG (eds) Clinical management of prostatic cancer. Year Book Medical, Chicago, pp 54–84

    Google Scholar 

  • Smith PH (1990) The case for no initial treatment of localized prostate cancer. Urol Clin North Am 17:827–834

    CAS  PubMed  Google Scholar 

  • Sökeland J (1974) Erfahrungen mit der radikalen Prostatektomie in Deutschland. Verh Dtsch Ges Urol 25:353–355

    Article  Google Scholar 

  • Solomon MH, McHugh TA, Dorr RP et al. (1993) Hormone ablation therapy as neoadjuvant treatment to radical prostatectomy. Clin Invest Med 16:532–538

    CAS  PubMed  Google Scholar 

  • Soloway MS, Hachiya T, Ruiz HE et al. (1993) Significance of androgen deprivation prior to radical prostatectomy, with special reference to prostate spezifîc antigen. World J Urol 11:221–226

    CAS  PubMed  Google Scholar 

  • Sommerkamp H, Altwein JE (1989) Lokale Tumorkontrolle — Effizienz kurativer Verfahren. In: Sommerkamp H, Altwein JE (Hrsg) Prostatakarzinom — Skektrum der kurativen Therapie. Karger, Basel, S 322

    Google Scholar 

  • Sonda LP (1991) Second-look prostate resection for incidental carcinoma of the prostate. In: Altwein JE, Faul P, Schneider W (eds) Incidental carcinoma of the prostate. Springer, Berlin Heidelberg New York Tokyo, pp 109–113

    Chapter  Google Scholar 

  • Stamey TA, Villers AA, McNeal JA et al. (1990) Positive surgical margins at radical prostatectomy: importance of the apical dissection. J Urol 143:1166–1173

    CAS  PubMed  Google Scholar 

  • Stamey TA, Kabalin JN, Ferrari M (1989) Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients. J Urol 141:1084

    CAS  PubMed  Google Scholar 

  • Stamey TA, Kabalin JK, McNeal JE et al. (1989) Prostate-specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. radical prostatectomy treated patients. J Urol 141: 1076–1083

    CAS  PubMed  Google Scholar 

  • Stamey TA, Kabalin JN, McNeal JE et al. (1989) Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II: Radical prostatectomy treated patients. J Urol 141 1076–1083

    CAS  PubMed  Google Scholar 

  • Stamey TA, Villers AA, McNeal JE et al. (1990) Positive surgical margins at radical prostatectomy: importance of the apical dissection. J Urol 143:1166–1172

    CAS  PubMed  Google Scholar 

  • Steiner MS, Morton RA, Walsh PC (1991) Impact of anatomical radical prostatectomy on urinary continence. J Urol 145:512–514

    CAS  PubMed  Google Scholar 

  • Stromberg J, Martinez A, Bonzalez J et al. (1995) Ultrasound-guided high dose rate conformai brachytherapy boost in prostate cancer: treatment description and preliminary results of a phase I/II clinical trial. Int J Radiat Oncol Biol Phys 33:161–171

    Article  CAS  PubMed  Google Scholar 

  • Sullivan LD, Rabbani F (1995) Should we reconsider the indications for ileo-obturator node dissection with localized prostate cancer. Br J Urol 75:33–37

    Article  CAS  PubMed  Google Scholar 

  • Sylora J, Kukadia A, Folstad A et al. (1994) Is bone scan necessary for prostate specific antigene 10. J Urol 1994:341A

    Google Scholar 

  • Ten Haken RK, Perez-Tamayo C, Tesser RJ et al. (1989) Boost treatment of the prostate using shaped fixed fields. Int J Radiat Oncol Biol Phys 16:193–200

    Article  PubMed  Google Scholar 

  • Theiss M, Wirth MP, Manseck A, Frohmüller HGW (1995) Prognostic significance of capsular invasion and capsular penetration in patients with clinically localized prostate cancer undergoing radical prostatectomy. Prostate 27:13–17

    Article  CAS  PubMed  Google Scholar 

  • Tomlinson RL, Currie DP, Boyce WH (1977) Radical prostatectomy: palliation for stage C carcinome of the prostate. J Urol 117:85–87

    CAS  PubMed  Google Scholar 

  • Trapasso JG, DeKernion JB, Smith RB, Dorey F (1994) The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 152: 1821–1825

    CAS  PubMed  Google Scholar 

  • Vahlensieck W, Jaeger N (1987) Reconstruction of the urethra by tube from a bladder flap during radical retropubic prostatectomy. Prog Clin Biol Res 243 6:395–398

    Google Scholar 

  • Villers A, McNeal JE, Freiha FS et al. (1993) Invasion of Denonvilliers’ fascia in radical prostatectomy specimens. J Urol 149:793–798

    CAS  PubMed  Google Scholar 

  • Walsh PC (1993) A decision analysis of alternative treatment strategies for clinically localized prostate cancer. J Urol 150:1330–1332

    CAS  PubMed  Google Scholar 

  • Walsh PC, Donker PJ (1982) Impotence following radical prostatectomy: insight into etiology and prevention. J Urol 128:492–497

    CAS  PubMed  Google Scholar 

  • Walsh PC, Schlegel PN (1987) Neuroanatomical approach to radical cystoprostatectomy with preservation of sexual function. J Urol 138:1402–1406

    PubMed  Google Scholar 

  • Walsh PC, Epstein JI, Lowe FC (1987) Potency following radical prostatectomy with wide unilateral excision of the neurovascular bundle. J Urol 138:823

    CAS  PubMed  Google Scholar 

  • Walsh PC, Brendler CB, Chang T et al. (1990) Preservation of sexual function in men during radical pelvic surgery. Md Med J 39:389–393

    CAS  PubMed  Google Scholar 

  • Walsh PC, Partin AW, Epstein JI (1994) Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 152:1831–1836

    CAS  PubMed  Google Scholar 

  • Wein AJ (1989) Editorial comment. J Urol 142:1229

    Google Scholar 

  • Whitmore WM (1973) The natural history of prostatic cancer. Cancer 32:1104

    Article  PubMed  Google Scholar 

  • Wilson DW, Harper ME, Jensen RM et al. (1985) A prognostic index for the clinical management of patients with advanced prostatic cancer. Prostate 7:131–141

    Article  CAS  PubMed  Google Scholar 

  • Wilt TJ, Brawer MK (1994) The prostate cancer intervention versus observation trial: a randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer. J Urol 152:1910–1914

    CAS  PubMed  Google Scholar 

  • Wolf JS, Cher M, Dall’era M et al. (1995) The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. J Urol 153:993–999

    Article  PubMed  Google Scholar 

  • Zagars GK, Ayala AG, von Eschenbach AC, Pollack A (1995) The prognostic importance of Gleason grade in prostatic adenocarcinoma: a long-term follow-up study of 648 patients treated with radiation therapy. Int J Radiat Oncol Biol Phys 31:237–245

    Article  CAS  PubMed  Google Scholar 

  • Zietman AL, Coen JJ, Dallow KC, Shipley WU (1995) The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome. Int J Radiat Oncol Biol Phys 32: 287–292

    Article  CAS  PubMed  Google Scholar 

  • Zincke H (1989) Salvage-Chirurgie bei lokalem Therapieversagen nach Strahlentherapie. In: Sommerkamp H, Altwein JE (Hrsg) Prostatakarzinom — Spektrum der kurativen Therapie. Karger, Basel, S 287

    Google Scholar 

  • Zincke H, Farrow GM, Myers RP et al. (1982) Relationship between grade and stage of adenocarcinoma of the prostate and regional pelvic lymph node metastases. J Urol 128:498

    CAS  PubMed  Google Scholar 

  • Zincke H, Utz DC, Taylor WF (1986) Bilateral pelvic lymphadenectomy and radical prostatectomy for clinical stage C prostate cancer: role of adjuvant treatment for residual cancer and in disease progression. J Urol 135:1199

    CAS  PubMed  Google Scholar 

  • Zincke H, Bergstralh EJ, Blute ML et al. (1994) Radical prostatectomy for clinically localized prostate cander: Long-term results of 1143 patients from a single institution. J Clin Oncol 12:2254–2263

    CAS  PubMed  Google Scholar 

  • Zincke H, Oesterling JE, Blute ML et al. (1994) Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2C or lower) prostate cancer. J Urol 152:1850–1857

    CAS  PubMed  Google Scholar 

  • Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J (1995) Long-term survival among men with conservatively treated localized prostate cancer. JAMA 274 (8): 626–631

    Article  CAS  PubMed  Google Scholar 

  • Bankneat RA (1992) Estramustine phosphate and other cytotoxic drugs in the treatment of poor prognostic advanced prostate cancer. Prostate [Suppl] 4:105–110

    Google Scholar 

  • Beckert R, Klima M, Altwein JE (1989) Chemotherapie des Prostatakarzinoms unter palliativer Zielsetzung? Urology 28: A 24

    Google Scholar 

  • Béland G (1991) Combination of anandron with orchiectomy in treatment of metastatic prostate cancer. Urology 37 [Suppl]: 25–29

    Article  PubMed  Google Scholar 

  • Beneventi FA, Noback GJ (1949) Distribution of the blood vessels of the prostate gland and urinary bladder: application to retropubic prostatectomy. J Urol 62:663–671

    CAS  PubMed  Google Scholar 

  • Benson RC Jr, Cummings K (1989) Estramustine phosphate vs diethylstilbestrol in the treatment of stage D prostate cancer. Prog Clin Biol Res 303:177–186

    PubMed  Google Scholar 

  • Benson RC, Gill GM, Cummings KB (1983) A randomized double blind crossover trial of diethylstilbestrol (DES) and estramustine phosphate (Emcyt) for stage D prostatic carcinoma. Sem Oncol 10:43–45

    Google Scholar 

  • Byar DP (1973) The VACURG studies of cancer of the prostate. Cancer 32:1126–1130

    Article  CAS  PubMed  Google Scholar 

  • Carrascosa M, Perez-Castrillon JL, Mendez MA, Cillero L, Valle R (1994) Malignant pleural effusion from prostatic adenocarcinoma resolved with hormonal therapy. Chest 105 (5): 1577–1578

    Article  CAS  PubMed  Google Scholar 

  • Caubet JF, Tosteson TD, Dong EW, Naylon E, Ernstoff MS, Ross S (1996) Metaanalysis of published randomized clinical trials for MAB in prostate cancer. Proc ASCO 15: Abstract 654

    Google Scholar 

  • Crawford ED (1989) Derzeitige Konzepte in der Behandlung des fortgeschrittenen Prostatakarzinoms. In: Altwein JE, Bartsch G (Hrsg) Therapie des fortgeschrittenen Prostatakarzinoms, PMI, Frankfurt, S 46–54

    Google Scholar 

  • Crawford ED, Eisenberger MA, McLeod DG et al. (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321:19–424

    Google Scholar 

  • Crawford ED, De Antoni EP et al. (1995) Prostate Cancer Awareness Week demonstrates continual value to early detection strategies. J Urol 153:312 A

    Google Scholar 

  • Crawford ED, De Antoni EP, Labrie F, Schröder FH, Geller J (1995) Therapeutic controversies. Endrocrine therapy of prostate cancer: Optimal form and appropriate timing. J Clin Endocrinol Metab 80:1062–1078

    Article  CAS  PubMed  Google Scholar 

  • Denis LJ, Murphy GP, Schröder FH (1995) Report of the consensus workshop on screening and global strategy for prostate cancer. Cancer 75:1187–1207

    Article  CAS  PubMed  Google Scholar 

  • Denis L, Smith P, Carneiro de Moura JL et al. (1991) Tota, androgen ablation: European experience. Uron Clin North Am 18:65–73

    CAS  Google Scholar 

  • Denis LJ, Carnelro-de-Moura JL, Bono A, Sylvester R, Whelan P, Newling D, Depauw M (1993) Go-serelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. Urology 42 (2): 119–130

    Article  CAS  PubMed  Google Scholar 

  • Denis LJ, Murphy GP, Schröder FH (1995) Report of the consensus workshop on screening and global strategy for prostate cancer. Cancer 75:1187–1207

    Article  CAS  PubMed  Google Scholar 

  • Ellis WJ, Isaacs JT (1985) Effectiveness of complete versus partial androgen withdrawal therapy for the treatment of prostatic cancer as studied in the Dunning R-3327 system of rat prostatic adenocarcinomas. Cancer Res 45:6041–6050

    CAS  PubMed  Google Scholar 

  • Fair WR (1986) Editorial — Hormonal therapy advanced prostatic cancer. J Urol 136:653–654

    CAS  PubMed  Google Scholar 

  • Ferro MA (1991) Use of intravenouas stilbestrol diphosphonate in patients with prostatic carcinoma refractory to conventional hormonal manipulation. Urol Clin N Am 18:139–143

    CAS  Google Scholar 

  • Fossa SD, Aaronson N, Calais de Silva F et al. (1989) Quality of life in patients with muscle-infiltrating bladder cancer and hormone-resistent prostate cancer. Eur Urol 16:335–339

    CAS  PubMed  Google Scholar 

  • Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K (1995) Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Uroloy 45 (5): 839–845

    Article  CAS  Google Scholar 

  • Griffiths K, Davies P, Eaton CL et al. (1991) Endocrine factors in the initiation diagnosis, and treatment of prostatic cancer. In: Voigt KD, Knobbe C (eds) Endocrine dependent tumors. Raven Press, New York, pp 83–130

    Google Scholar 

  • Grundmann E (1988) Neue Möglichkeiten der Krebsnachsorge. Dtsch ärztebl 85:959

    Google Scholar 

  • Grups JW (1988) Langzeitergebnisse der radikalen Prostatektomie. Urologe A 27:348–351

    CAS  PubMed  Google Scholar 

  • Hovespian JA, Byar DP, Vacu RG (1975) Carcinoma of the prostate. Correlation between radiologic quantification of metastases and patient survical. Urology 6:11–16

    Article  Google Scholar 

  • Hsu DS, Babaian RJ (1983) 5-Fluorouracil, adriamycin, mitomycin-C (FAM) in the treatment of hormonal-resistant stage D adenocarcinoma of the prostate (abstract C-250). Proc Am Soc Clin Oncol 133:05250

    Google Scholar 

  • Jones H, Anthony PP (1992) Metastatic prostatic carcinoma presenting as left-sided cervical lym-phadenopathy: a series of 11 cases. Histopathology 21 (2): 149–154

    Article  CAS  PubMed  Google Scholar 

  • Jordan WP, Blackard CE, Byar DP (1977) Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma. South Med J 70:1411–1413

    PubMed  Google Scholar 

  • Kramolowsky EV (1988) The value of testosterone deprivation in stage D1 prostatic carcinoma. J Urol 139:1242

    CAS  PubMed  Google Scholar 

  • Kröpfl D, Krause R, Härtung R (1988) A method to avoid lymphoceles in heparinised patients. J Urol 139:168

    Google Scholar 

  • Labrie F, Dupont A, Bélanger A et al. (1983) New approach in the treatment of prostate cancer: complete instead of only partial withdrawal of androgens. Prostate 4:579–584

    Article  CAS  PubMed  Google Scholar 

  • Logothetis CJ, Hossan E, Dexeus FH, Sella A, Amato RJ, Killoum RG (1990) Primary combined chemotherapy and hormonal therapy for the treatment of patients with avanced metastatic adenocarcinoma of the prostate. J Urol 143:309A

    Google Scholar 

  • McLeod DG, Crawford ED, Blumenstein BA et al. (1992) Controversies in the treatment of metastatic prostate cancer. Cancer 70:324–328

    Article  CAS  PubMed  Google Scholar 

  • Mencel PJ, DeAngelis LM, Motzner RJ (1994) Hormonal ablation as effective therapy for carcinomatous meningitis from prostatic carcinoma. Cancer 73 (7): 1892–1894

    Article  CAS  PubMed  Google Scholar 

  • Murphy GP, Beckly S, Brady MF et al. (1983) Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 51:1264–1271

    Article  CAS  PubMed  Google Scholar 

  • Murphy GP, Huben RP, Priore R et al. (1986) Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer. Urology 28:36–40

    Article  CAS  PubMed  Google Scholar 

  • Myers RP, Zincke P, Fleming TR (1983) Hormonal treatment at time of radical prostatectomy for stage D1 prostate cancer. J Urol 130:99–101

    CAS  PubMed  Google Scholar 

  • Neri R, Kassem N (1984) Biological and clinical properties of antiandrogens. Prog Cancer Res Ther 31:507–518

    CAS  Google Scholar 

  • Nesbit RM, Plumb RT (1946) Prostatic carcinoma: follow-up on 795 patients treated prior to endocrine era and comparison of survival rates between these and patients treated by endocrine therapy. Surgery 20:263–270

    CAS  PubMed  Google Scholar 

  • Newling DWW, McLeod D, Soloway M et al. (1992) Distant diesease. Cancer 70:365–367

    Article  CAS  PubMed  Google Scholar 

  • Pummer K, Lehnert M, Seewann HL (1993) Chemohormonal and immunohormonal approaches in advanced prostatic carcinoma. Eur Urol 24 [Suppl] 2:81–86

    Google Scholar 

  • Skipper HE (1971) Kinetics of mammary tumor all growth and implications for therapy. Cancer 28: 1479–1499

    Article  CAS  PubMed  Google Scholar 

  • Smith PH, Suciu S, Robinson MRG et al. (1986) A comparison of the effect of diethylstilbestrol with low dose estramustine phosphate in the treatment of avanced prostatic cancer: final analysis of a phase III trial of the EORTC. J Urol 136:619–623

    CAS  PubMed  Google Scholar 

  • Steenbrugge van GJ, Groen M, Bold-de Vried J et al. (1985) Human prostate cancer (PC-82) in nude mice: a model to study androgen regulated tumor growth. In: Schröder FH, Richards B (eds) EORTC GU Group Monograph 2, part A. Liss, New York, pp 23–33

    Google Scholar 

  • Tubiana M, Malaise P (1976) Growth rate and cell kinetics in human tumors: some prognostic and therapeutic implications. In: Symington T, Carter RL (eds) Scientific foundations of oncology. Heinemann, London, pp 126–135

    Google Scholar 

  • Tyrell CJ, Altwein, JE, Klippel F et al. (191) A multicenter randomized trial comparing the LH-RH analogue gosereline axcetate alone with flutamide in the tratment of advanced prostate cancer. J Urol 146:1321–1326

    Google Scholar 

  • Vandenbroucke F, Van-Poppel H, Derluyn J, Popelier G, Casselman J, Billiet I, Vanuytsel L, Paridaens R, Baert L (1995) Interim results on a randomized trial of mitomycin C in combination with orchidectomy for newly diagnosed metastatic prostate cancer. Am J Clin Oncol 18 (3): 263–266

    Article  CAS  PubMed  Google Scholar 

  • Anfield FJ, Schroeder J, Curreri AR (1962) Five years clinical experience with 5-fluorouracil. JAMA 181:295–299

    Article  Google Scholar 

  • Berry WR, MacDonald RN (1982) Cisplatin, cyclophosphamide, and prednisone therapy for stage D prostatic cancer. Cancer Treat Rep 66:1403–1404

    CAS  PubMed  Google Scholar 

  • Blum RH (1975) An overview of studies with adriamycin (NSC-123127) in the United States. Cancer Chemother Rep 6/3:247–251

    Google Scholar 

  • Boccardo F, Cannata D, Guarneri D, Oneto F, Cortesi E, Bono A (1994) R 75251 in prostate cancer patients in progression after first-line hormonal treatment. Tumori 80:276–279

    CAS  PubMed  Google Scholar 

  • Broders AC (1922) Ephithelioma of genito-urinary organs. Ann Surg 75:574–604

    Article  CAS  PubMed  Google Scholar 

  • Budd GT, Osgord B, Barna B et al. (1989) Phase I clinical trial of interleukin 2 and α-interferon toxicity and immunologic effects. Cancer Res 49:6432–6436

    CAS  PubMed  Google Scholar 

  • Bui NB, Chauvergne J, Brunet R et al. (1986) Metastatic cancer of the prostate: phase II study of spirogermanium (NSC 192965). Bull Cancer (Paris) 73:65–75

    CAS  Google Scholar 

  • Bulbul MA, Ruben RP, Murphy GP (1986) Interferon-beta treatment of metastatic prostate cancer. J Surg Oncol 33:231

    Article  CAS  PubMed  Google Scholar 

  • Burk K, Schultze-Seemann W, de Riese W, Hanke P, Weber W (1986) Die ambulante zytostatische Therapie des hormonrefraktären Prostata-Carcinoms mit 4-Epirubicin. 38. Kongr Dt Ges f Urologie (Abstractband). Demeter, Gräfelfing, S 176

    Google Scholar 

  • Canobbio L, Boccardo F, Guarneti D et al. (1992) A phase II evaluation of carboplatin (CBDCA) in hormone-resistant cancer. Ann Oncol 3 [Suppl 5]: 112

    Google Scholar 

  • Carter SK, Wassermann TH (1975) The chemotherapy of urologic cancer. Cancer 36:729–747

    Article  CAS  PubMed  Google Scholar 

  • Chang AYC (1986) Toxicities of human recombinant interferon alpha in 2 patients with advanced prostate carcinoma. J Interferon Res 6:713–715

    Article  CAS  PubMed  Google Scholar 

  • Chlebowski RT, Herstorff R, Sardoff L, Weiner J, Bateman JR (1978) Cyclophosphamide versus the combination of adriamycin, 5-fluorouracil, and cyclophosphamide in the treatment of metastatic prostatic cancer. Cancer 42:2546–2552

    Article  CAS  PubMed  Google Scholar 

  • Citrin DL, Hogan TF (1982) A phase II evaluation of adriamycin and cisplatinum in hormone-resistant prostatic cancer. Cancer 50:201–206

    Article  CAS  PubMed  Google Scholar 

  • Cooper EH, Armitage TG, Robinson MRG et al. (1990) Prostate specific antigen and the prediction of prognosis in metastatic prostate cancer. Cancer 66:1025–1028

    CAS  PubMed  Google Scholar 

  • Cooper EH, Robinson MRG, Whelan P et al. (1992) Tumor markers in prostate cancer. Cancer 70:225–229

    Article  CAS  PubMed  Google Scholar 

  • Dawson NA, McLeod DG (1995) Dramatic prostate specific antigen decrease in response to discontinua of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal snyndrome. J Urol 153:1947–1949

    Article  Google Scholar 

  • DeKernion JN, Murphy GD, Priore R et al. (1988) Comparison of flutamide and emcyt in hormone-refractory metastatic prostate cancer. Urology 31:312–317

    Article  CAS  Google Scholar 

  • Deshpande N et al. (1989) Divergent effects of interferons on benign prostate hyperplasia cells (BPH) in primary culture. J Urol 141:157

    CAS  PubMed  Google Scholar 

  • DeWys WD, Begg CG, Brodosky H, Creech K, Khandekar J (1983) A comparative clinical trial of adriamycin and 5-fluorouracil in advanced prostatic cancer: prognostic factors and response. Prostate 4:1–11

    Article  CAS  PubMed  Google Scholar 

  • Dexeus F, Logothetis CJ, Samuels MC (1985) Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer. Cancer-Treat Rep 69:885

    CAS  PubMed  Google Scholar 

  • Drelichman A, Brownlee R, Al-Sarraf M (1981) Phase II study of hexamethylmelamine for disseminated prostatic carcinoma. Cancer Clin Trials 4:309–312

    CAS  PubMed  Google Scholar 

  • Eagen RT, Hahn RG, Myers RR (1976) Adriamycin (NSC-123127) versus 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in the treatment of metastatic prostate cancer. Cancer Treat Rep 60:115–117

    Google Scholar 

  • Dupont A, Gomez JL, Cusan L, Koutsilieris M, Labrie F (1993) Response to flutamide withdrawal in advanced prostate cancer in progress under combination therapy. J Urol 150:908–913

    CAS  PubMed  Google Scholar 

  • Figg WD, Thicault A, Cooper MR et al. (1995) A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer. Cancer 75:2159–2164

    Article  CAS  PubMed  Google Scholar 

  • Ernst DS, Hanson J, Venner PM (1991) Analysis of prognostic factor in men with metastatic prostate cancer. Uro-oncology group of Northern Alberta. J Urol 146:372–376

    CAS  PubMed  Google Scholar 

  • Ferro MA (1991) Use of intravenous stilbestrol diphosphonate in patients with prostatic carcinoma refractory to conventional hormonal manipulation. Urol Clin N Am 18:139–143

    CAS  Google Scholar 

  • Fossa SD, Urnes T, Kaalhus O (1987) Weekly low-dose adriamycin in hormone-resistant cancer of the prostate. Scand J Urol Nephrol 21:13–16

    Article  CAS  PubMed  Google Scholar 

  • Goldschmidt AJW, Bauer L, Tunn UW (1990) Third-line Therapie des metastasierenden Prostatakarzinoms mit Interferon. Aktuel Onkol 57:73–82

    Google Scholar 

  • Goldstein D, O’Leary M, Mitchen J et al. (1991) Effects of interferon b ser and transforming growth factor b on prostatic cell lines. J Urol 146:1173–1177

    CAS  PubMed  Google Scholar 

  • Graf-Dobberstein C, Rubben H, Otto U, Block T (1990) Systemic chemotherapy of endocrine-resistant prostate carcinoma with cisplatin and mitomycin: Final results of a prospective multicenter trial. Eur Urol 18 [Suppl 1]: 132

    Google Scholar 

  • Graff J, Pastor J, Bertels C, Demetriou D, Schulze H (1990) Erfahrungen mit der Chemotherapie beim metastasierten Prostatakarzinom. Aktuel Urol 21:1–6

    Article  Google Scholar 

  • Hall BE, Good JW (1962) Treatment of far advance cancer with 5-fluorouracil used alone and in combination with irradiation: incidence and duration of remission and survival data in 223 patients. Cancer Chemother Rep 16:369–386

    CAS  PubMed  Google Scholar 

  • Hayward S, Cox S, Mitchell I (1987) The effects of interferons on the activity of alpha-glycerol-phosphate dehydrogenase in benign prostatic hyperplasia cells in primary culture. J Urol 138: 648–653

    CAS  PubMed  Google Scholar 

  • Herr HW (1982) Cyclophosphamide, methotrexate and 5-fluorouracil combination chemotherapy versus chloroethyl-cyclohexanitrosourea in the treatment of metastatic prostatic cancer. J Urol 127:462–465

    CAS  PubMed  Google Scholar 

  • Houghton AL, Robinson MRG, Smith PH (1977) Melphalan in advanced prostatic cancer: a pilot study. Cancer Treat Rep 61:923–924

    CAS  PubMed  Google Scholar 

  • Hsu DS, Babaian RJ (1983) 5-Fluorouracil, adriamycin, mitomycin-C (FAM) in the treatment of hormonal-resistant stage D adenocarcinoma of the prostate (abstract C-250). Proc Am Soc Clin Oncol 133:C5250

    Google Scholar 

  • Humphrey EW, Hymes AC, Ausman RK et al. (1961) An evaluation of actinomycin-D and mitomycin-C in patients with advanced cancer. Surgery 50:881–885

    CAS  PubMed  Google Scholar 

  • Ihde DC, Bunn PA, Cohen MH (1981) Combination chemotherapy as initial treatment for stage D2 prostatic cancer (abstract 648). Proc Am Assoc Cancer Res 124:163

    Google Scholar 

  • Johnson DE, Scott WW, Gibbons RP, Prout GR, Schmidt JD, Murphy GP (1976) Clinical significance of serum acid phosphatase levels in advanced prostatic carcinoma. Urology 8:123–126

    Article  CAS  PubMed  Google Scholar 

  • Jones WG, Fossa SD, Denis L, Coninx P, Glashan RW, de Pauw M (1983) An EORTC phase II study of vindesine in avanced prostate cancer. Eur J Cancer Clin Oncol 19:583–588

    Article  CAS  PubMed  Google Scholar 

  • Jones WG, Fossa SD, Bono AV, Croies JJ, Stoter G, de Pauw M, Sylvester R, members of the Genito-Urinary Tract Cooperative Group (1986) Mitomycin-C in the treatment of metatatic prostate cancer: report on a EORTC phase II study. World J Urol 4:182–185

    Article  Google Scholar 

  • Karnofsky DA, Abelman WH, Craver LF, Burchenal JH (1948) The use of the nitrogen mustards in the palliative treatment of carcinoma. Cancer 1:634–656

    Article  Google Scholar 

  • Kasimis BS, Moran EM, Miller JB (1983) Treatment of hormone-resistant metastatic cancer of the prostate with 5-fluorouracil, doxiorubicin and mitomycin-C (FAM): a preliminary report. Cancer Treat Rep 67:937–939

    CAS  PubMed  Google Scholar 

  • Kasimis BS, Miller BJ, Kaneshiro CA, Forbes KA, Moran EM, Metter GE (1985) Cyclophosphamide versus 5-fluorouracil, doxorubicin, and mitomycin-C (FAM) in the treatment of hormone-resistant metastatic carcinoma of the prostate: a preliminary report of a randomized trial. J Clin Oncol 3:385–392

    CAS  PubMed  Google Scholar 

  • Kennealey GT, Marsh JC, Walsh PA (1978) Treatment of advanced carcinoma of the prostate with estramustine and 5-fluorouracil (5-FU) (abstract C-351). Proc Am Soc Clin Oncol 111:394

    Google Scholar 

  • Knabbe C, Kellner U, Voigt KD (1991) Growth factors in human prostate cancer cells: implications for an improved treatment of prostate cancer. J Steroid Biochem Molec Biol 40:185–192

    Article  CAS  PubMed  Google Scholar 

  • Kofmann S, Eisenstein R (1963) Mithramycin in the treatment of disseminated cancer. Cancer Chemother Rep 32:77–96

    Google Scholar 

  • Kotake RT, Miki T, Akaza H et al. (1991) Effect of recombinant granulocyte colony-stimulating factor (RF-CSF) on chemotherapy-induced neutropenia in patients with urogenital cancer. Cancer Chemother Pharmacol 27:253–257

    Article  CAS  PubMed  Google Scholar 

  • Labrie F, Dupont A, Cusan L, Gomez JL, Diamond P (1993) Major advantages of „early” administration of endocine combination therapy in advances prostate cancer. Clin Invest Med 16:493–498

    CAS  PubMed  Google Scholar 

  • Lerner HJ, Malory TR (1977) Hydroxyurea in stage D carcinoma of prostate. Urology 10:35–38

    Article  CAS  PubMed  Google Scholar 

  • Liu S, Ewing MW, Anglard P et al. (1991) The effect of suramin, tumor necrosis factor and interferon α on human prostatic cancinoma. J Urol 145:389–392

    CAS  PubMed  Google Scholar 

  • Lloyd RE, Jones SE, Salmon SE, Durie BGM, McMahon CJ (1976) Combination chemotherapy with adriamycin (NSC-123127) and cyclophosphamide (NSC-26271) for solid tumors: a phase II trial. Cancer Treat Rep 60:77–83

    CAS  PubMed  Google Scholar 

  • Loening SA, Beckley S, Brady MF et al. (1983) Comparison of estramustine phosphate, methotrexate, and cisplatinum in patients with advanced hormone-refractory prostate cancer. J Urol 129:1001–1006

    CAS  PubMed  Google Scholar 

  • Logothetis CJ, Samuels ML, von Eschenbach AC, Trindade A, Ogden S, Grant C, Johnson DE (1983) Doxorubicin, mitomycin-C and 5-fluorouracil (DMF) in the treatment of metastatic hormone-refractory adenocarcinoma of the prostate with a note on the staging of metastatic prostate cancer. J Clin Oncol 1:368–378

    CAS  PubMed  Google Scholar 

  • Medenica RD, Slack N (1985 a) Clinical results of leukocyte interferon-induced tumor regression in resistant human metastatic cancer resistant to chemotherapy and/or radiotherapy-pulse therapy schedule. Cancer Drug Deliv 2:53–76

    Article  CAS  PubMed  Google Scholar 

  • Medenica RD, Slack N (1985 b) Immunomodulatory activity of human leucocyte interferon in cancer patients: results obtained during pulse therapy schedule. Cancer Drug Deliv 2:91–118

    Article  CAS  PubMed  Google Scholar 

  • Merrin CE (1978) Treatment of advanced carcinoma of the prostate (stage D) with infusion of cis-diamine-dichloroplatinum (II NSC-119875): a pilot study. J Urol 119:522–524

    CAS  PubMed  Google Scholar 

  • Merrin CE (1979) Treatment of genitourinary tumors with cis-dichlorodiamine-platinum (II): experience in 250 patients. Cancer Treat Rep 63:1579–1589

    CAS  PubMed  Google Scholar 

  • Merrin CE, Etra W, Wajsman Z, Baumgartner G, Murphy GP (1976) Chemotherapy of advanced carcinoma of the prostate with 5-fluorouracil, cyclophosphamide, and adriamycin. J Urol 115: 86–88

    CAS  PubMed  Google Scholar 

  • Moore GE, Bross IDJ, Ausman R et al. (1968) Effects of 5-fluorouracil (NSC-19893) in 389 patients with cancer: Eastern Clinical Drug Evaluation Program. Cancer Chemother Rep 52:641–653

    CAS  PubMed  Google Scholar 

  • Moore MR, Trôner MB, DeSimone P, Birch R, Irwin L (1986) Phase II evaluation of weekly cisplatinum in metastatic hormone-resistant prostate cancer: a Southeastern Cancer Study Group trial. Cancer Treat Rep 70:541–542

    CAS  PubMed  Google Scholar 

  • Mundi AR (1982) A pilot study of hydroxyurea in hormone „escaped” metastatic carcinoma of the prostate. Br J Uriol 54:20–25

    Article  Google Scholar 

  • Murphy GP, Gibbons RP, Johnson DE et al. (1977) A comparison of extramustine phosphate and streptozotocin in patients with prostatic carcinoma who had extensive irradiation. J Urol 118:288–291

    CAS  PubMed  Google Scholar 

  • Murphy GP (1988) Management of metastatic prostatic cancer. Prog Clin Biol Res 277:127–134

    CAS  PubMed  Google Scholar 

  • Murphy GP, Priore RL, Scardino PT (1988) Hormone-referactory metastatic prostatic cancer treated with methotrexal cyclophosphamid plus adriamycin, cis-platinum plus 5-fluorouracil plus cyclophosphamide. National prostatic cancer project randomized trial. Urology 32:33–40

    Article  CAS  PubMed  Google Scholar 

  • Muss HB, Howard V, Richards F et al. (1981) Cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil in advanced prostatic cancer: a randomized trial. Cancer 47:1949–1954

    Article  CAS  PubMed  Google Scholar 

  • Natale RB, Yagoda A, Watson RC, Stover DE (1980) Phase II trial of neocarcinostatin in patients with bladder and prostatic cancer. Cancer 45:2836–2842

    Article  CAS  PubMed  Google Scholar 

  • Nichols WC, Kvols LK, Richardson RL (1982) A phase II study of aziridinylbenzoquinone (AZQ) in advanced genitourinary (GU) cancer. Proc Am Soc Clin Oncol 125:117

    Google Scholar 

  • Niijima T, Ro 22–8181 Oncology Study Group (1985) Clinical efficacy of recombinant human leucocyte A interferon (r IFN-a A) on malignant tumors of the urogenital tract. Jpn J Cancer Chemother 12:921–927

    Google Scholar 

  • Nissen N I, Pajak TF, Leone LA (1980) Clinical trial of VP-16–213 (NSC-141540) IV twice weekly in advanced neoplastic disease: a study by the Cancer and Leukemia Group B. Cancer 45:232–235

    Article  CAS  PubMed  Google Scholar 

  • O’Bryan RM, Luce JK, Talley RW et al. (1973) Phase II evaluation of adriamycin in human neoplasia. Cancer 32:1–8

    Article  PubMed  Google Scholar 

  • O’Bryan RM, Baker LH, Gottlieb JE et al. (1977) Phase II evaluation of adriamycin in human neoplasia. Cancer 39:1940–1948

    Article  PubMed  Google Scholar 

  • Orava M, Cantrell K, Vikho R (1986) Treatment with preparations of human leucocyte interferon decreases serum testosteron concentrations in men. Int J Cancer 38:295–296

    Article  CAS  PubMed  Google Scholar 

  • Osborn JL, Getzenberg RH, Trump DL (1995) Spinal cord compression in prostate cancer. J Neuro-oncol 23:35–47

    Article  Google Scholar 

  • Osborne CK, Craig JB, Klein K, Crawford ED, Turner J (1989) Phase II trial of a new biological response modified (Imuvert) in advanced prostate cancer. Invest New Drugs 7:243–245

    Article  CAS  PubMed  Google Scholar 

  • Otto T, Al-Enzawi S, Rembrink K (1994) Empfehlungen zur systemischen Chemotherapie des hormonrefraktären Prostatakarzinoms. Urol [B] 34:192–196

    Google Scholar 

  • Otto T, Goepel M, Rembrink K (1994) Seltene Tumoren der Prostata. Urol [B] 34:273–274

    Google Scholar 

  • Otto T, Rembrink K, Goepel M, Krege S, Rübben H (1996) Die Therapie des hormonrefraktären Prostatakarzinoms mit Mitoxantron. Urol [A] 35:1–4

    Google Scholar 

  • Paulson DF, Berry WR, Cox EB, Walker A, Laszlo J (1979) Treatment of metastatic endocrine unresponsive carcinoma of the prostate gland with multiagent chemotherapy: indicators of response to therapy. J Natl Cancer Inst 53:615–622

    Google Scholar 

  • Pavone-Macaluso M, Lund F, Mulder JF (1980) EORTC protocols in prostatic cancer. Scand J Urol Nephrol 55 [Suppl]: 163–168

    CAS  Google Scholar 

  • Perloff M, Ohnuma T, Holland JF (1977) Adriamycin (ADM) and diaminedichloroplatinum (DDP) in advanced prostatic carcinoma (PC). Proc Am Soc Clin Oncol 99:333

    Google Scholar 

  • Qazi R, Khandekar J (1983) Phase II study of cisplatinum for metastatic prostatic carcinoma: an Eastern Cooperative Oncology Group study. Am J Clin Oncol (CCT) 6:203–205

    Article  CAS  Google Scholar 

  • Quarmby VE, Yarbrough WG, Lubahn DB et al. (1990) Autologous down-regulation of androgen receptor messenger ribonucleic acid. Mol Endocrinol 4:22

    Article  CAS  PubMed  Google Scholar 

  • Rosen P, Belldegrun A (1995) American studies on suramon therapy in hormone resistant prostate cancer. Cancer Surv 23:231–234

    CAS  PubMed  Google Scholar 

  • Rossof AH, Talley RW, Stephens R et al. (1979) Phase II evaluation of cis-dichloro-diamineplati-num (II) in advanced malignancies of the genitourinary and gynecological organs: a Southwest Oncology Group study. Cancer Treat Rep 63:1557–1565

    CAS  PubMed  Google Scholar 

  • Scher H, Yagoda A, Watson R, Serber M, Whitmore W (1984) Phase II trial of adriamycin in bidi-mensionally measurable prostatic adenocarcinoma. J Urol 131:1099–1102

    CAS  PubMed  Google Scholar 

  • Scher H, Yagoda A, Ahmed T et al. (1985) Phase II trial of mitognazone in bi-dimensionally measurable hormone resistant prostatic carcinoma. J Clin Oncol 3:224–228

    CAS  PubMed  Google Scholar 

  • Schmidt JD, Scott WW, Gibbons RP et al. (1979) Comparison or procarbazine, imdiazol-carboxa-mide, and cyclophosphamide in relapsing patients with advanced carcinoma of the prostate. J Urol 121:185–189

    CAS  PubMed  Google Scholar 

  • Sica G, Fabbronni L, Dell’Aqua G (1989) Antiproliferative effect of interferons on human prostate carcinoma cell lines. Urol Res 17:111

    Article  CAS  PubMed  Google Scholar 

  • Slack NH (1983) Results of chemotherapy protocols of the USA National Prostatic Cancer Project (NPCP). Clin Oncol 2:441–459

    Google Scholar 

  • Smalley RV, Bartolucci AA, Hemsteet G, Hester M (1981) A phase II evaluation of a 3-drug combination of cyclophosphamide, doxirubicin, and of 5-fluorouraciol in patients with advanced bladder carcinoma or stage D prostatic carcinoma. J Urol 125:191–195

    CAS  PubMed  Google Scholar 

  • Soloway MS (1988) Adenocarcinoma of the prostate. Stage-by-stage treatment alternatives. Postgrad Med 84:44–46

    CAS  PubMed  Google Scholar 

  • Soloway MS (1988) Efficacy of buserelin in advanced prostate cancer and comparison with historical controls. Am J Clin Oncol II [Suppl 1):S29–32

    Google Scholar 

  • Soloway MS, Shippel RM, Ikard M (1979) Cyclophosphamide, doxorubicin hydrochloride and 5-fluorouracil in advanced carcinoma of the prostate. J Urol 122:637–639

    CAS  PubMed  Google Scholar 

  • Soloway MS, DeKernion JB, Gibbons RP et al. (1981) Comparison of estramustine phosphate and vincristine alone or in combination for patients with advanced hormonerefractory, previously irradiated carcinoma of the prostate. J Urol 125:664–667

    CAS  PubMed  Google Scholar 

  • Soloway MS, Beckley S, Brady MF et al. (1983) A comparison of estramustine phosphate versus cisplatinum alone versus estramustine phosphate plus cis-platinum in patients with advanced hormone-refractory prostate cancer who had extensive irradiation to the pelvis or lumbosacral area. J Urol 129:56–61

    CAS  PubMed  Google Scholar 

  • Stephens RL, Vaughn C, Lane M et al. (1984) Adriamycin and cyclophosphamide versus hydroxyurea in advanced prostatic cancer. Cancer 53:406–410

    Article  CAS  PubMed  Google Scholar 

  • Takadu F (1987) Effect of treatment of malignant tumors with recombinant interferon a. Jpn J Cancer Chemother 14:645–652

    Google Scholar 

  • Tejeda F, Eisenberger MA, Broder LA (1977) 5-fluorouracil versus CCNU in the treatment of metastatic prostate cancer. Cancer Treat Rep 6:1589–1590

    Google Scholar 

  • Tilley WD, Marcelli M, Wilson JD et al. (1989) Characterization and expression of a cDNA encoding the human androgen receptor. Proc Natl Acad Sci USA 86:327

    Article  CAS  PubMed  Google Scholar 

  • Torti FM, Aston D, Lum BL (1983) Weekly doxorubicin in endocrine refractory carcinoma of the prostate. J Clin Oncol 1:477–482

    CAS  PubMed  Google Scholar 

  • Torti FM, Shortliffe LD, Carter SK (1985) A randomized study of doxorubicin versus doxorubicin plus cis-platinum in endocrine unresponsive metastatic prostatic carcinoma. Cancer 56:2580–2586

    Article  CAS  PubMed  Google Scholar 

  • Trump DL, Loprinzi CL (1984) Phase II trial of etoposide in advanced prostate cancer. Cancer Treat Rep 68:1195

    CAS  PubMed  Google Scholar 

  • Trump D, Smith D, Bahnson R et al. (1992) All-trans-retinoic acid (tRA) in hormone-refractory prostate cancer — a new approach to therapy and prevention. Third Annual Pittsburgh cancer conference, Nov 19–20

    Google Scholar 

  • Tubiana M, Malaise P (1976) Growth rate and cell kinetics in human tumors: some prognostic and therapeutic implications. In: Symington T, Carter RL (eds) Scientific foundations of oncology. Heinemann, London, pp 126–135

    Google Scholar 

  • Uzbicki RM, Amer RH, Al-Sarrat M (1979) Combination of adriamycin and cyclophosphamide in the treatment of metastatic prostatic carcinoma. Cancer Treat Rep 63:999–1001

    Google Scholar 

  • Vandenbroucke F, Van Poppel H, Derluyn J et al. (1995) Am J Clin Oncol 18:263–266

    Article  CAS  PubMed  Google Scholar 

  • Walther PJ, Williams SD, Troner M, Greco AF, Birch R, Einhorn LH, Southeastern Cancer Study Group (1986) Phase II Study of etoposide for carcinoma of the prostate. Cancer Treat Rep 70:771–772

    CAS  PubMed  Google Scholar 

  • Wein AJ (1989) Editorial comment. J Urol 142:1229

    Google Scholar 

  • Weiss AG, Jackson LA, Carabasi RI (1961) An evaluation of 5-fluorouracil in malignant disease. Ann Intern Med 55:731–741

    CAS  PubMed  Google Scholar 

  • Wirth MP (1990) Wertigkeit der Chemotherapie in der Behandlung des fortgeschrittenen Prostatakarzinoms. In: Frohmüller HGW, Wirth MP (Hrsg) Behandlung des fortgeschrittenen Prostatakarzinoms. Springer, Berlin Heidelberg New York Tokyo, S 14–21

    Chapter  Google Scholar 

  • Yagoda A, Watson RC, Natale RB, Barteil W, Sogani P, Grabstald W, Whitmore WF (1979) A critical analysis of response criteria in patients with prostatic cancer treatment with cis-diamine-dichloride platinum (II). Cancer 44:1553–1562

    Article  CAS  PubMed  Google Scholar 

  • Yoshimoto J, Tsushima T, Matsumura Y et al. (1985) Phase II study of recombinant human leucocyte A interferon on urogenital cancer patients. Jpn J Cancer Chemother 12:465–470

    CAS  Google Scholar 

  • Altwein JE, Jocham D, Schrott KM, Wirth M, Hölzel D (1989) Empfehlungen zur Tumornachsorge (Prostata). Bayer ärztebl 44:10

    Google Scholar 

  • Bagshaw MA (1980) External radiation therapy of carcinoma of the prostate. Cancer 45:1912

    CAS  PubMed  Google Scholar 

  • Berry WR, Laszlo J, Cox E, Walker N, Paulson DF (1979) Prognostic factors in metastatic and hor-monally unresponsive carcinoma of the prostate. Cancer 44:763–775

    Article  CAS  PubMed  Google Scholar 

  • Bishop MC, Ansell ID, Taylor MC, Thomas AL (1985) Serial prostatic histology. A valid marker of response to hormone treatment. Br J Urol 57:453

    Article  CAS  PubMed  Google Scholar 

  • Chodak GW, Vogelzang NJ, Caplan RJ et al. (1991) Independent prognostic factors in patients with metastatic (stage D) prostate cancer. JAMA 265:618–621

    Article  CAS  PubMed  Google Scholar 

  • Gittes RF (1991) Carcinoma of the prostate. N Engl J Med 324:236

    Article  CAS  PubMed  Google Scholar 

  • Hodge KK, McNeal JE, Terris MK et al. (1989 a) Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 142:71–75

    CAS  PubMed  Google Scholar 

  • Hodge KK, McNeal JE, Stamey TA (1989 b) Ultrasound guided treatrectal core biopsies of the palpably abnormal prostate. J Urol 142:66–70

    CAS  PubMed  Google Scholar 

  • Hölzel D, Sauer H, Waal JC (1988) Tumornachsorge-Schemata: Wissensinhalt — Anwendung — Optimierung. Onkologie 11:202

    Article  PubMed  Google Scholar 

  • Hovsepian JA, Byar DP, Vacu RG (1975) Carcinoma of the prostate. Correlation between radiologic quantification of metastases and patient survical. Urology 6:11–16

    Article  CAS  PubMed  Google Scholar 

  • Kabalin JN, Hodge KK, McNeal JE et al. (1989) Identification of residual cancer in the prostate following radiation therapy: role of transrectal ultrasound guided biopsy and prostate specific antigen. J Urol 142:326

    CAS  PubMed  Google Scholar 

  • Killian GS, Yang N, Emrich LJ et al. (1985) Prognostic importance of prostate-specific antigen for monitoring patients with stage B2 to D1 prostate cancer. Cancer Res 45:886

    CAS  PubMed  Google Scholar 

  • Merrick MV, Ding CL, Chisholm GG, Elton RA (1985) Prognostic sigificance of alkaline and acid phosphatase and skeletal scientigraphy in carcinoma of the prostate. Br J Urol 57:795

    Article  Google Scholar 

  • Oesterling JE, Chan DW, Epstein JL et al. (1988) Prostate specific antigen in the preoperative and postoperative evaluation of localized prostate cancer treated with radical prostatectomy. J Urol 139:766–772

    CAS  PubMed  Google Scholar 

  • Otto T, Goepel M, Rembrink K (1994) Seltene Tumoren der Prostata. Urol [B] 34:273–274

    Google Scholar 

  • Di Sant’Agnese PA (1995) Neuroendocrine Differentiation in Prostatic Carcinoma. Cancer 75 [Suppl]: 1850–1859

    Article  Google Scholar 

  • Smith JA, Cho YH (1990) Management of stage A prostate cancer. Urol Clin N Am 17:769–777

    Google Scholar 

  • Smith PH (1990) The case for no initial treatment of localiced prostate cancer. Urol Clin N Am 17:827–834

    CAS  Google Scholar 

  • Sommerkamp H, Altwein JE (1989) Lokale Tumorkontrolle — Effizienz kurativer Verfahren. In: Sommerkamp H, Altwein JE (Hrsg) Prostatakarzinom — Spektrum der kurativen Therapie. Karger, Basel, S 322

    Google Scholar 

  • Stamey TA, Kabalin JN, Ferrari M (1989) Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients. J Urol 141:1084

    CAS  PubMed  Google Scholar 

  • Zagers GK, Eschenbach AC von (1993) Prostate specific antigen: An important marker for prostate cancer treated by external beam radiotherapy. Cancer 72:538–548

    Article  Google Scholar 

  • Zincke H (1989 d) Salvage-Chirurgie bei lokalem Therapieversagen nach Strahlentherapie. In: Sommerkamp H, Altwein JE (Hrsg) Prostatakarzinom — Spektrum der kurativen Therapie, Karger, Basel, S 287

    Google Scholar 

Download references

Authors
  1. J. E. Altwein
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Urologische Klinik und Poliklinik, Medizinische Einrichtungen der Universität-GHS Essen, Hufelandstraße 55, 45122, Essen, Deutschland

    Herbert Rübben (Direktor der Urologischen Klinik und Poliklinik) (Direktor der Urologischen Klinik und Poliklinik)

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Altwein, J.E. (1997). Prostatakarzinom. In: Rübben, H. (eds) Uroonkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-10731-7_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-10731-7_7

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-10732-4

  • Online ISBN: 978-3-662-10731-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation